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Insulin-like growth factor I (IGF-I) has widespread effects on the regulation of 
proliferation and differentiation of many cell types, as well as insulin-like metabolic 
effects on glucose metabolism. Most circulating IGF-I is bound to high-affinity 
insulin-like growth factor binding proteins (IGFBPs), to form a high molecular 
weight tertiary complex and constitutes the primary reservoir of circulating IGF-I. 
The binding of IGF-I to its binding protein prolongs the half-life and titrates the 
access of this hormone to its receptors. Recombinant human insulin-like growth 
factor I (rhIGF-I) produced by E. coli has been shown to reduce plasma glucose and 
insulin levels in subjects with severe insulin resistance. Co-administration of IGF-I 
with one of the binding protein, insulin-like growth factor binding protein 3 
(IGFBP-3) has been shown to reduce the side effects of IGF-I without affecting the 
therapeutic efficacy. A major drawback on the use of recombinant IGF-I and 
IGFBP-3 as a therapeutic agent is the limited supply of the peptide. 
It has been demonstrated that plants such as tobacco can be used as bioreactors 
to produce animal proteins at low costs. We plan to express and produce 
recombinant human IGF-I and IGFBP-3 in tobacco plants using different expression 
constructs. 
iv 
Various constructs with different temporal and spatial expression patterns were 
thus designed and introduced into the tobacco plants by Agrobacterium-mQd\?iit& 
transformation. Promoters used to drive the expression of IGF-I and IGFBP-3 were 
seed-specific phaseolin promoter or constitutive cauliflower mosaic virus (CaMV) 
35S promoter. Other constructs contained additional sequences including the 
targeting tetrapeptide signal (AFVY) of phaseolin protein and the winged bean 
lysine-rich protein (LRP) as fusion receptor protein, with an aim to enhance the 
expression level of target proteins in transgenic plants, through targeting the proteins 
into compartments for storage or to increase protein stability. Southern blot 
analysis confirmed that integration of target DNA into the plant genome. For the 
IGFBP-3 transgenic plants, mRNA was detected for all the constructs, whereas two 
constructs with IGF-I (phaseolin promoter and phaseolin promoter with targeting 
signal) failed to transcribe. Failure of transcript detection may be due to gene 
silencing or unstable mRNA. Preliminary results revealed that four lines of 
transgenic plants were able to produce IGF-I and IGFBP-3, including the IGF-I/LRP 
* 
and IGFBP-3/LRP fusion constructs, and the IGFBP-3 constructs contain phaseolin 
signal peptide with or without the targeting signal. The expression level could 
amount to 0.4% of the total seed protein. 
Our results demonstrate that transgenic plants can be developed as a 
XV 
bioreactor for the synthesis of human IGF-I and IGFBP-3. Future studies will be 
required to test the biological activities of these recombinant proteins following their 
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Chapter 1 Overview 
Diabetes mellitus is a common disorder affecting about 10% of Hong Kong 
Chinese. Compared to the Caucasians, Chinese patients with type 2 diabetes are 
younger, thinner and have a high incidence of insulin deficiency (Lam et ai, 2000). 
The early age of onset of diabetes implies longer disease duration and higher risk of 
developing devastating complications. Abnormal regulation of growth hormone 
(GH) / insulin-like growth factor-I (IGF-I) axis is well documented in patients with 
diabetes, particularly among those who are insulin deficient. Low IGF-I levels have 
also been associated with ageing and development of obesity, both of which are 
closely associated with development of type 2 diabetes (Heald et al, 2001; Bang et 
al., 1994). 
It has been demonstrated that treatment with recombinant human IGF-I (rhIGF-I) 
could improve glycaemic control and reduce the requirement of insulin doses in type 
2 diabetes. Besides the adverse effects which are commonly associated with high 
'dose rhlGF.-I therapy could be alleviated with the addition of recombinant human 
IGF binding protein-3 (rhIGFBP-3) to rhIGF-I (Clemmons et al, 2000). 
The key limiting step in the development of rhIGF-I and rhIGFBP-3 as 
therapeutic option is the availability of recombinant proteins at low cost. So, it 
1 
would be valuable to produce large amount and high quality of rhIGF-I and 
rhIGFBP-3 using different recombinant DNA technology. One of these approaches 
is to use plants as bioreactors. Using plants as bioreactors has advantages including 
low cost, large quantity and high quality. 
In this study, the cDNA encoding the plant-optimized human IGF-I or IGFBP-3 
was used to construct chimeric genes with different temporal and spatial expression 
patterns. These chimeric genes were delivered into tobacco genome via 
Agrobactehum-mQ6\diXQ& transformation and their expressions were analyzed. 
) 
2 
Chapter 2 Literature Review 
2.1 Historical background 
With changing demographics and rapid socio-economical developments, 
diabetes has become a major global health problem. Hong Kong has one of the 
highest prevalence of diabetes of 10% in modem societies. Using both clinic-based 
and population-based studies, 20-30% of our diabetic patients develop disease before 
the age of 40 (Chan et al., 1993; Lam et al, 2000). In contrast to the Caucasians, 
who mainly suffered with autoimmune type 1 diabetes, young patients in Hong Kong 
is extremely heterogeneous in terms of etiology and clinical course (Ng et al, 2001). 
Only 10-30% of young patients have presentation of type 1 diabetes and 50% of 
them with type 2 presentation eventually require insulin therapy (Ko et al., 1998). 
This finding reflects the impaired insulin secretion from the underlying pancreatic 
p-cell failure. Given the association between disease duration and vascular 
complications of diabetes, it is imperative that strict glycaemic control should be 
‘achieved to minimize the risk of developing these devastating complications. 
I 
Diabetes is a progressive disease resulting from the interactions between 
pancreatic p-cell failure, obesity and ageing. To date, treatment of diabetes is still 
focused on the relationship between plasma glucose and insulin. The role of 
J 
age-related hormonal changes, in particular, GH/IGF-I axis on the development of 
obesity and the progression of diabetes has not been fully understood. Heald et al. 
(2001) suggested that abnormalities in the regulation of IGF-I play a role in the 
development of insulin resistance. There is an inverse relationship between IGF-I 
and metabolic control. In patients with type 2 diabetes, the insulin-treated group 
with the highest hemoglobin Ale (HbAlc) had the lowest IGF-I level (Heald et al, 
2001: Bang et aL 1994). It is plausible that elevation of IGF-I level may improve 
glycaemic control in patients with insulin-treated diabetes. 
According to Ballard et al (1989), circulating IGF-I levels are relatively stable 
mainly due to its constitutive pattern of secretion and the binding of IGF-I to 
high-affinity binding proteins. Six IGF-binding proteins have been identified. 
Among the six binding proteins, IGF-binding protein 3 (IGFBP-3) binds more than 
95% of IGF-I in serum. The IGF-I/IGFBP-3 dimer will finally form a complex 
with the acid-labile subunit (ALS) (Binoux and Hossenlopp, 1988). 
I 
4 
2.2 Insulin-like growth factor 
2.2.1 Structure and synthesis 
Insulin-like growth factors (IGFs), also known as somatomedins, belong to a 
family of polypeptide hormones. IGF-I and IGF-II are the first two peptides 
isolated from human blood. IGF-I is a single polypeptide with three intrachain 
disulfide bridges and is encoded by a single gene on chromosome 12. It contains 70 
amino acid residues (Figure 2- 1) and has a molecular weight of 7646. (Rinderknecht 
and Humbel, 1978; Brissenden and Francke, 1984). IGF-I consists of four 
contiguous domains, termed B，C, A, and D and is structurally similar to proinsulin 
which contains B, C, and A regions. 
IGF-I is released into the blood mostly by the liver and reaches the target cells 
in the classic endocrine manner (LeRoith, 1997). The IGF-I production is mainly 
regulated by GH, insulin, and nutrition. IGF-I levels start out very low in the 
newborn, reach a maximum during puberty and return to an intermediate level during 
'adulthood (Zapfe/ ai, 1981; Hall and Sara, 1984). 
5 
Figure 2-1 IGF-I structure 
IGF-I, consisting of 70 amino acid residues (a. a.), contains a 
N-terminal B region of 29 a. a.，a central C domain of 12 a. a., an A 
domain of 21 a. a., and a C-terminal D region of 8 a. a. 
2.2.2 Physiologic role and biological actions 
Most of the cellular effects of IGF-I is mediated by the binding of the peptide to 
the receptor (Werner et al, 1991). Three types of receptors can bind with IGF-I: 
insulin, IGF-I and insulin/IGF-I receptors. The IGF-I receptor has a high degree of 
homology with the insulin receptor and is the only IGF receptor confirmed to have 
IGF-mediated signaling functions. The hybrid IGF/insulin receptors can bind IGF-I 
* 
) 
and potentially transmit a cytoplasmic signal. At higher IGF-I concentrations, the 
insulin receptors can also be stimulated. The hybrid insulin/IGF-I receptors can 
form in cells that express both receptor genes. These hybrid receptors have ligand 
specificity profiles more comparable to the IGF-I receptor than to the insulin receptor, 
6 
causing a signaling cascade that is very similar to the response from phosphorylation 
of the insulin receptor (Jones and Clemmons, 1995). 
IGF-I receptors are present in a wide variety of cell types and mediated most of 
IGF-I in vitro, as well as the effects of insulin when this hormone is present in 
sufficiently high concentration. In general, IGF-I gave either acute anabolic effects 
on protein and carbohydrate metabolism, or longer-term effects on cell replication 
and differentiation in vitro; therefore IGF-I can mimic all the growth-promoting 
actions of GH (Laron et aL, 1992). 
The precise role of IGF-I in the regulation of carbohydrate metabolism is not yet 
defined. In healthy people, recombinant human IGF-I (rhIGF-I) can exert an acute 
hypoglycaemic effect, but the effect was proved to be 10 times less potent than that 
of insulin in equivalent dose (Guler et aL, 1987). However, IGF-I has a more 
pronounced effect in protein metabolism, decreasing overall net amino acid flux 
compared to equivalent glucose lowering doses of insulin (Boulware et aL, 1992). 
Furthermore, IGF-I is a potent inhibitor of pancreatic insulin release (Guler et aL, 
'1987). , 
7 
2.3 Insulin-like growth factor b ind ing protein-3 
2.3.1 Structure and synthesis 
Insulin-like growth factor binding protein-3 (IGFBP-3) belongs to a family of 
homologous proteins that bind IGF-I with high affinities. Upon binding to IGF-I, 
IGFBP-3 can form a high molecular weight complex with the ALS to prolong the 
half life of IGF-I, is a tightly regulated source of circulating IGF-I (Rajaram et ai, 
1997). From the sequence of human ICTFBP-3 CDNA, it has been estimated that the 
core protein consists of 264 amino acids, and has a molecular weight of around 
29000 (Wood et ai, 1988). There are three potential N-glycosylation sites 
(Asn-X-Ser/Thr) in the IGFBP-3 central region. In both cellular and plasma 
sources, native human IGFBP-3 is usually found as a characteristic doublet of 
approximately 40-45 kDa (Martin and Baxter, 1986). 
According to Zapf et al. (1979), IGFBP-3 is the main carrier of IGF-I in serum 
which is synthesized in multiple tissues except the liver. Therefore it is available in 
-extracellular fluids to modulate IGF actions. > 
2.3.2 Physiologic role and biological actions 
IGFBP-3 has four major essential functions to coordinate and regulate the 
biological activities of IGF-I. IGFBP-3 controls the efflux of IGF-I from the 
8 
vascular space by acting as transport protein in plasma. It prolongs the half-lives of 
IGF-I and regulates their metabolic clearance. Moreover, it provides a means of 
tissue and cell type-specific localization. Lastly, it modulates the inter-action of 
IGF-I with the receptor directly and thereby control biological actions indirectly 
(Jones and Clemmons, 1995). 
IGFBP-3 has been demonstrated to have direct effects on cellular activities such 
as stimulation and inhibition of cell proliferation (Jones and Clemmons, 1995)， 
induction of apoptosis (Gill et al, 1997; Rajah et al, 1997) and nuclear translocation 
(Jaques et al., 1997; Schedlich et ai, 1998). Many of these cellular functions may 
require the association of IGFBP-3 with the cell surface. Although it was suggested 
that the post-translational modification of the cell surface proteins and its localization 
to the cell surface may modulate its bioactivity, the factors that distinguish the 
inhibitory and stimulatory effects of IGFBP-3 on cell growth are not fully understood 




2.4 Cl in ical aspects 
2.4.1 Metabolic effects of IGF-I 
IGF-I exerts metabolic effects via the type 1 IGF-I receptor and the insulin 
receptor. The cross-reaction of IGF-I with the insulin receptor is important in the 
metabolic effects of IGF-I both in vitro and in vivo (Figure 2- 2). Growth hormone 
and insulin is that GH and insulin stimulate the constitutive secretion of IGF-I from 
the liver (Phillips et aL, 1990) and IGF-I, in turn, suppresses GH and insulin 
secretion, even under euglycaemic conditions (Renneert et al., 1993; Zenobi et al,, 
1992). Circulating IGF-I is relatively stable in comparing to the highly regulated 
secretory patterns and the fluctuating serum profiles of GH and insulin. This may 
be due to its constitutive pattern of secretion and its binding to the high-affinity 
IGFBPs, which prolong the half-life and titrate the supply of IGF-I to its receptors 
(Baxter, 1993). To date, six IGFBPs have been identified and IGFBP-3 is the one 
with most abundant clinical data. As mentioned in the earlier section, IGFBP-3 
binds IGF-I and the acid-labile subunit (ALS) to form a high molecular weight > 
ternary complex, which constitutes the primary reservoir of circulating IGF-I. 
Circulating levels of this complex are positively regulated by GH. Another IGFBP, 
IGFBP-1, also binds a smaller fraction of the total circulating IGF-I, but the effects 
10 
of IGF-I on intermediary metabolism may not be proportionately influential as 
IGFBP-1 levels which are potently suppressed by insulin. Inferences from the 
metabolic regulation of IGFBP-1 have important implications in relation to diabetic 
subjects as IGFBP-1 functions as a counter-regulator (Lewitt et al., 1991). 
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Figure 2- 2 Complementary anabolic actions of insulin and IGF 
(Adopted from Zapfer al, 1999) 
2.4.L1 Similarities between IGF-I and insulin 
The similarities of the biological actions of IGF-I and insulin has been known 
> 
since the discovery of nonsuppressible insulin-like activity (NSILA) in serum at the 
beginning of the 1960s (Froesch et al, 1963). IGF-I is of 48% sequence identity in 
amino acid with proinsulin (Clemmons et al, 2000). Both the A and B domains of 
IGF-I contain sequences that can be aligned to identical regions in human insulin. 
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Thus, a three-dimensional (3-D) model for IGF-I has been deduced based on the 
folding of human proinsulin (Blundell et al., 1978). 
The similarity between IGF-I and insulin extends further to their receptors, 
where the IGF receptor displays a 50-60% homology to the insulin receptor (Ullrich 
et al, 1986). Because of the high sequence homology between IGF-I and insulin, 
IGF-I and insulin can cross-react at each other's receptor. These common features 
can explain why IGF-I mimics all the biological actions of insulin investigated so far 
(Table 2- 1). 
Table 2-1 Similarities between IGF-I and insulin 
1) amino acid sequence about 45% homology of A and B domain with 
insulin A and B chain 
2) three-dimensional structure folding identical to proinsulin 
3) signaling pathway tyrosine kinase ~ • phosphorylation of IRS-1~~• 
activation of phosphatidylinositol-3-kinase and 
SH2-containing proteins 
4) biological actions IGF-I mimics all biological actions of insulin 
'(Adopted from Zapfe/ al, 1999) 
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2.4.1.2 Differences between IGF-I and insulin 
According to Froesch et al. (1963), the major structural differences between the 
3-D models of IGF-I and proinsulin occur in the C domain. The C domain of IGF-I 
is shorter than that of proinsulin. Locating on the hydrophilic surface of the 
molecule, the C domain is involved in the interaction with the hormone receptor and 
antibodies (Rinderknecht and Humbel, 1978). The structural dissimilarity of the C 
domain explain the differences in the competitive potencies between insulin and 
IGF-I at each other's receptors, their biological potencies and the lack of 
cross-reactivity between them and their antibodies. The major differences between 
IGF-I and insulin are listed in Table 2- 2. 
There are several important biological differences between IGF-I and insulin. 
Firstly, insulin is produced only by the pancreatic (3-cell. However, IGF-I can be 
produced by many tissues but mainly in the liver and it acts in both endocrine and 
auto/paracrine manners. Insulin secretion occurs by emeiocytosis in a pulsatile 
manner in response to the fluctuations of the serum glucose concentration, whereas 
IGF-I is released constantly under the influence of GH. The total serum level of 
IGF-I is about 300 times higher than the basal insulin levels, whereas free IGF-I 
levels are in a range similar to those of basal serum insulin levels (Frystyk et al., 
1994). 
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The main physiological function of insulin is the regulation of fuel homeostasis, 
whereas IGF-I is a growth and differentiation factor that act on growth through IGF-I 
receptor. Moreover, IGF-I also exerts acute metabolic effects in vitro and in vivo. 
Table 2- 2 Major differences between IGF-I and insulin 
IGF-I Insulin  
1) structure 1 chain; 2 chain; 
C domain conserved; C peptide cleaved off; 
additional D domain no D domain 
2) site of production most tissues, pancreatic P-cell 
mainly in the liver 
3) secretion constant, slow release emeiocytosis, pulsatile 
secretion 
4) main physiological growth hormone glucose 
stimulus 
5) physiological role growth and differentiation fuel homeostasis 
(via type 1 IGF receptor) (via insulin receptor) 
(Adopted from Zapfet aL, 1999) 
2.4.2 Glucose and protein metabolism 
Most tissues and cells have type 1 IGF-I receptors on the plasma membrane and 
/ 
respond to IGF-I in an insulin-like manner. 
Rat adipose tissue was the first tissue used to study the effects of insulin on 
glucose and lipid metabolism, as it is exquisitely sensitive to insulin. Like insulin, 
IGF-I can enhance glucose uptake and net gas exchange in rat adipose tissue (Zapf et 
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al, 1978). Both peptides stimulate glucose uptake, glucose oxidation, and lipid 
synthesis from glucose in isolated rat fat cells. 
The perfused rat heart responded to IGF-I in a dose-dependent manner at IGF-I 
concentrations from 10'^  to lO'^M and resulted in increased glucose uptake and 
lactate production (Meuli and Froesch, 1975; Meuli and Froesch, 1976). In contrast 
to adipose tissue，the biological potency ratio between IGF-I and insulin in this 
model was higher than that in adipose tissue. A similar conclusion was reached 
from studies in isolated mouse soleus muscle. In this in vitro model, IGF-I 
stimulated 2-deoxyglucose uptake, glycolysis, and glycogen synthesis; activated 
glycogen synthase and enhanced protein synthesis (Monier et al, 1983). 
In cultured adult rat hepatocytes, half-maximal concentrations of IGF-I for 
insulin stimulated glycolysis (Hartmann et al., 1990). Like insulin, IGF-I also 
inhibited basal and glucagons-activated glycogenolysis, with a 50 to 100-fold lower 
potency. 
2.4.3 As a therapeutic agent 
Since 'IGF-I was identified as one of the protein responsible for the 
"nonsuppressible insulin-like activity" by Froesch et al. in 1963, IGF-I has been an 
attractive candidate in the diabetes mellitus treatment. As IGF-I shares not only 
structural homology but also cognates receptor and post-receptor signaling 
15 
similarities with insulin. IGF-I may have a greater mitogenic potential than insulin, 
this may be due to the sharp contrast of the half-life of IGF-I complex which is stable 
over 24 hours compared to insulin which is measured in minutes. This may be 
responsible for the prolonged activation of mitogenic signaling pathways through the 
IGF-I receptor by levels of IGF-I that are sustained in both the plasma and 
extracellular compartments (Gabbay and Moses, 1999). Large-scale production of 
rhIGF-I has led to an explosion in research for characterization of the metabolic 
effects and therapeutic actions of IGF-I in different forms of diabetes. 
2.4.3.1 Type 1 diabetes mellitus 
The deregulation of GH/IGF axis in insulin dependent (type 1) diabetes mellitus 
(IDDM) is characterized by a state of functional GH resistance in which GH is 
elevated and IGF-I is decreased (Dunger et al., 1995); this elevation in GH may 
underlie the worsening of glycaemic control seen in many adolescents with type 1 
diabetes. 
Several studies have examined the efficacy of rhIGF-I in type 1 diabetic patients. 
A continuous 10-hour infusion of rhIGF-I was shown to decrease overnight 
arginine-stimulated GH levels and lower nocturnal insulin requirements (Bach et al., 
1994). Cheetham et al. (1994) demonstrated that a subcutaneous dose of 40 ug/kg 
at bedtime similarly decreased GH secretion. An extension of this dosage for 4 
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weeks decreased GH and improved glycaemic control (as measured by a 1% 
decrease in HbAlc) in the six adolescent type 1 diabetic patients treated with 
rhIGF-I. 
2.4.3.2 Type 2 diabetes mellitus 
In patients with type 2 diabetes mellitus, who have failed therapy with diet or 
hypoglycaemic agents, insulin is often used as an alternative therapy. However, 
insulin may not necessarily correct the underlying insulin resistance. It was 
proposed that rhIGF-I could avoid insulin resistance in generally obese patients by 
reducing hyperglycaemia through effects at the IGF-I receptor. The potential 
effectiveness of rhIGF-I in severe insulin resistance was first demonstrated by 
observing reductions in serum glucose and plasma insulin in three patients with type 
A insulin resistance syndrome after an acute intravenous bolus of rhIGF-I (Schoenle 
et al., 1991). Further research by Morrow et al. (1994) reported that subcutaneous 
administration of rhIGF-I in two subjects with the type A syndrome led to improved 
glycaemic control, reduced fasting and postprandial serum insulin levels and 
‘improved insulin sensitivity. In 1995, Moses et al. extended these observations to 
six subjects with various forms of severe insulin resistance and Kuzuya et al. (1993) 
demonstrated similar findings in seven patients followed up for one year while 
receiving rhIGF-I. Another study of Zenobi's group (1992) investigated 8 subjects, 
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during a 5-day subcutaneous infusion of rhIGF-I and observed reductions in fasting 
and postprandial glucose levels together with improvements in lipid metabolism. 
Short-term IGF-I infusion enhances lipid oxidation (Hussain et al., 1993); 
Longer-term studies were carried out by Schalch et al. in 1993 by using a large 
subcutaneous dose of IGF-I. These confirmed that rhIGF-I could improve 
glycaemic control and reduce the body fat, particularly intraabdominal fat. Each of 
these changes could contribute to the change in insulin sensitivity. 
Moses et al. completed an open label study of rhIGF-I in 12 subjects with 
NIDDM of 6 weeks duration in 1996. All subjects had poor glycaemic control at 
the beginning of the study and 9 of the 12 completed at least 4 weeks of rhlGF-I 
therapy. In these patients, there was a dramatic improvement in glycaemic control 
with reductions in HbAlc and fructosamine. The mechanism whereby low doses of 
rhlGF-I could reduce hyperglycaemia and improve insulin sensitivity is unclear, 
given the fact that the overall glucose lowering potential of rhIGF-I is only one-tenth 
of that of insulin. 
‘ Levels of GH and glucagons were reduced by rhIGF-I therapy (Boulware et al, 
1992). Reduction in GH and glucagons could lead to decreased levels of free fatty 
acid and improvements in insulin sensitivity. Their results support the notion that 
IGF-I replacement therapy may be of therapeutic benefit in patients with diabetes. 
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2.4.4 Side effects 
Since IGF-I can stimulate cell proliferation and promote cell survival, elevated 
or prolonged IGF-I stimulation may promote cellular transformation. The 
mitogenic and antiapoptotic effects of IGF-I are thought to be mediated by the type I 
IGF receptor, which possesses ligand-activated tyrosine kinase activity (Massague 
and Czech, 1982). Multiple case studies demonstrated that elevated serum IGF-I 
levels and low IGFBP-3 levels are associated with an increased risk of prostate, 
colorectal, breast and lung cancers (Chan et al‘, 1998; Pollak, 2000). 
It had been reported that a dosage of 90- 160 ug/kg body weight were tolerated 
in subjects with type 2 diabetes mellitus for short period only. But if treatment was 
continued for longer duration, side effects became limiting (Moses, 1997). The side 
effects observed in the initial studies of rhIGF-I therapy in NIDDM subjects were 
dose-related and have not been replicated in more recent studies using lower doses. 
A major problem associated with administration of free IGF-I was the induction of 
side effects (Jabri et al., 1994), particularly at doses ^80 ug/kg twice daily. Mild 
'side effects, such as edema, jaw pain and headaches occur in more than 80% of the 
subjects and serious side effects, such as Bell's palsy and retinal edema, in 10-15% 
of such patients. Some early reports of severe bradycardia and other arryhthymias 
were not confirmed with large scale studies, but acute hypophosphatemia has been 
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reported after acute intravenous administration, and sinus tachycardia has been noted 
after a dose of subcutaneous rhIGF-I (Moses, 1997). 
However, when IGF-I was administered with IGFBP-3 to normal volunteers at 
higher doses than that were tolerated in previous studies, side effects were not 
observed (Sanders et aL, 1997). Similarly, no side effect was observed when 
IGF-I/IGFBP-3 combination was administered to a group of 12 elderly osteoporotic 
women with status post hip fracture for 2 months (Geusens et al, 1998). These 
findings suggest that IGFBP-3 can limit the side effects, probably by changing free 
IGF-I levels and the distribution of IGF-I among the various binding proteins in 
serum. Although this regimen seems to limit IGF-I-associated side effects, the 
question whether IGFBP-3 would also reduce the efficacy of IGF-I remains. Till 
now, the short-term beneficial metabolic effects of rhIGF-I therapy have been 
demonstrated in many diabetic cases. However, the long-term safety and metabolic 
efficacy of rhIGF-I therapy remains to be established (Thrailkill, 2000). 
20 
2.5 World demands 
2.5.1 Significance of large-scale production 
During the last ten years, an explosion of new information has confirmed and 
extended our understanding of the pleiotropic effects of the IGF system on growth, 
development and intermediary metabolism. Many recent advances in the basic 
biology of IGF-I and IGFBP-3, provide further insight on the regulation of cell and 
tissue survival, growth and differentiation. However, one of the major obstacles in 
the research of IGF-I and IGFBP-3 is the cost of production of the recombinant 
proteins. 
2.5.2 IGF-I production 
Up to now, rhIGF-I is mainly produced from microbes such as Escherichia coli 
(Chung et al., 2000). Other sources include sarcoma cell lines (Bernstein et aL, 
2001) and transgenic mice (Su et aL, 1999). However, these expression systems are 
、、 
not sufficient for large scale IGF-I production because of the high equipment and 
production cost as well as the potential contamination with pathogens. In an 
attempt to circumvent these problems, we propose to synthesize rhIGF-I and 
rhIGFBP-3 in plants using the transgenic approach. 
Unlike many organisms, plants cells can be engineered to accept and express 
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genetic information from a wide range of organisms, including genes from 
prokaryotic and eukaryotic sources (Walden and Wingender, 1995). Furthermore, 
plants cells like their animal counterparts are eukaryotic in nature, they are able to 
produce mammalian proteins with the appropriate post-translational modifications 
(e.g. glycosylation, prenylation and formation of disulfide bridges) often necessary 
for proper protein or enzyme function. 
The seeds of many plant species are edible and it is possible to accumulate the 
recombinant proteins in seeds. In some instances, the recombinant proteins may not 
require further processing and purification which offering the option of oral delivery. 
Dosage level and frequency will be strictly controlled for individual cases as each 
protein characteristics such as acid and protease resistance varies among each protein 
(Mason et al, 2002). Delivery vehicles such as bioencapsulation and plant tissues 
may be used to prevent degradation of protein in the stomach and gut before they can 
elicit an immure system (Daniell et al., 2001). Sardana et al. (2002) have 
developed seed-based platforms for the biological assembly and production of 
pharmaceutical proteins. Their results suggest that the use of plant seeds as a > 
vehicle to produce and deliver biopharmaceuticals via the ‘seed as pill' route has 
important implications for the future. 
One limitation of using transgenic plant is the low levels of pharmaceutical 
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proteins in total soluble protein of the seed (Kusnadi et al., 1997). To enhance 
expression, focus is on the development of efficient promoters especially to target the 
production of proteins into edible parts and on factors such as enhancers, signal 




2.6 Plants as bioreactors 
2.6.1 Medical molecular farming 
Medical molecular fanning is the production of pharmaceutically important and 
commercially valuable proteins in plants. Its purpose is to provide a safe and 
inexpensive means for the mass production of recombinant proteins (Fischer and 
Emans, 2000). Bacteria were often the first choice for protein expression while 
yeast cells and baculovirus infected insect cell lines were of minor importance 
(Skerra, 1993; Taticek et al, 1994). Although bacteria are convenient production 
system, they are incapable of producing post-translational modifications that are 
necessary for the activity of many mammalian proteins. This limitation and the cost 
of expression of proteins in mammalian cell lines prompted the exploration of plants, 
as a cheap, safe and efficient alternative. 
2.6.2 Advantages of plant bioreactor 
Plants are good candidates to produce human proteins. The production and 
scale-up costs are relatively low as no expensive equipment (fermenter) or growth 
) 
medium/supplement is required. Also, many proficient modern agricultural 
processes for harvest, transport, storage and processing of grains are available, where 
the amount of product produced in plant can reach industrial-scale levels. 
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Purification for the product can be omitted if they are expressed in consumable plant 
tissues. Plants can provide efficient post-translational processing which often 
necessary for proper protein folding and function. The passage of transgene from 
generation to generation in a Mendelian fashion in plants can lead to high yield of 
proteins in grains from future generations (Arakawa et al., 1999). Furthermore, 
contamination of expressed proteins with human or animal pathogens or other 
infectious diseases will not occur in plants (Fischer and Emans, 2000). 
2.6.3 Commercial biopharmaceutical protein 
An interesting study of molecular farming for production of recombinant avidin 
in plant was conducted by Hood et al. in 1997. Avidin is a relatively abundant 
protein found in egg white and is widely used as a diagnostic reagent for 
immobilizing, purifying and visualizing proteins due to its binding characteristics to 
other proteins. The rationale was to produce avidin in transgenic corn and 
determine if this could compete with egg white as a commercial source of the protein. 
The result demonstrated that avidin could be produced at 230 mg per kg of maize 
seed and the plant-produced avidin is 10-fold less expensive than avidin extracted 
from eggs. This maize avidin is functional and commercially available now 
(Sigma-Aldrich product # A8706), illustrates how a relatively abundant protein with 
a rich natural source can be produced less expensively in plants. 
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2.7 Tobacco expression system 
2.7.1 Tobacco as model plant 
Tobacco {Nicotiana tabacum) belongs to the Solanaceae family, which is a leafy 
dicotyledonous plant. It is one of the most widely adopted model plant used in 
transgenic experiments primarily because it is readily transformed and subsequently 
regenerated into whole, fertile plants. Tobacco is normally growing as annual crop 
and is capable of self-fertilization to produce abundant seeds for analysis. 
2.7.2 Transformation methods 
Agrobacterium tumefaciens co-cultivation is the major method to introduce the 
foreign genes into plant tissues at present. Agrobacterium is a nature genetic 
engineer; it is capable to transform a range of dicotyledonous plants by transferring 
plasmid-encoded genes into recipient plant genomes. Co-integration of chimeric 
genes into the T-DNA between the border sequences of wild-type Ti (tumor-inducing) 
plasmid enabled such genes to be introduced into plant genome. Horsch et al 
(1985) developed a very simple leaf disk method for plant transformation. 
> 
Basically, it involves immersion of leaf disks in a liquid culture of Agrobacterium 
carrying the chosen transformation vector; cocultivation of leaf disks with 
Agrobacterium-, and the transfer of infected leaf disks to suitable medium for plant 
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regeneration. 
Biolistic gene transfer (particle bombardment) is another commonly used 
physical process for plant transformation. It involves the delivery of 





2.8 Hypotheses and aims of study 
Treatment with rhIGF-I has been shown to improve glycaemic control and the 
requirement of insulin doses. The addition of rhIGFBP-3 to rhIGF-I alleviates the 
adverse effects that are commonly associated with high-dose rhIGF-I therapy. 
In this proposal, we aim to study the feasibility of expressing human IGF-I and 
IGFBP-3 cDNAs in tobacco for the production of recombinant proteins. The 
hypotheses are: 
a) the plant-optimized IGF-I and IGFBP-3 cDNAs could be recognized by 
and expressed in plant; 
b) the expression, stability and accumulation of the modified IGF-I and 
IGFBP-3 could be enhanced in transgenic plants with different chimeric 
gene constructs controlling the spatial and temporal expression and the 
stability and subcellular targeting of the protein products. 
In this study, expression vectors representing different temporal and spatial 
expression will be designed to drive the plant-optimized IGF-I and IGFBP-3 cDNAs 
* 
\ 
and introduced into the tobacco plants via Agrobacterium-mQdidXQd transformation. 
The expression of the transgenes will be analyzed with different molecular 
approaches. 
The production of rhIGF-I and rhIGFBP-3 in sufficient quantity from transgenic 
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plant will stimulate further studies in the treatment of patients and development of 




Chapter 3 Expression of Human IGF-I and IGFBP-3 
in Transgenic Tobacco 
3.1 Introduction 
Human IGF-I and IGFBP-3 cDNAs were first codon modified to optimize their 
expression in plants. To find out whether the plant-optimized IGF-I and IGFBP-3 
cDNAs were transcribed and translated or not in plants, transient assay of their GUS 
fusion genes using particle bombardment were performed. After the transient assay, 
the transgenes were synthesized in transgenic tobacco plant using different 
expression constructs. Various constructs with different temporal and spatial 
expression patterns were designed and introduced into the tobacco plants by 
Agrobacterium-mQ6\diXQ(\ transformation. Promoters for the expression of IGF-I and 
IGFBP-3 were seed-specific phaseolin (Phas) promoter or constitutive cauliflower 
mosaic virus (CaMV) 35S promoter. Other constructs contained additional 
sequences including the phaseolin signal peptide (SP), the targeting tetrapeptide 
signal (AFVY) of phaseolin protein, the winged bean lysine-rich protein (LRP) gene 
I 
or p-glucuronidase (GUS) gene as fusion receptor. These constructs were 
synthesized to increase the expression of protein and to target proteins into 
compartments for storage as well as to enhance protein stability. 
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3.2 Materials and methods 
3.2.1 Chemicals 
All chemicals used were of reagent grade or molecular grade unless otherwise 
noted. Restriction enzymes and other modifying enzymes were obtained from New 
England Biolabs Inc. (Beverly, MA, USA) and Promega Biosciences (Madison, WI, 
USA) unless specified. 
3.2.2 Plant materials 
Tobacco {Nicotiana tabacum L. cv Xanthin. nc) was used as the model plant 
system in this study. Seeds of wild type tobacco were surface sterilized in 50% 
Clorox (5.25% sodium hypochlorite) and 0.04% Tween-20 for 10 minutes with 
vigorous shaking, followed by washing with sterilized distilled water 5 times, each 
for 1 minute. Sterilized seeds were allowed to germinate on MS agar (42.4g/L MS 
basal medium (Sigma, MS-9274), pH5.7) and grow at 25。C with a 16-hour 
photoperiod. Tobacco leaves about one-month old were used for 
Agrobacterium-mQ6\?iXQdi transformation. After transformation, regenerated 
transgenic tobacco plants were transferred to soil and greenhouse for seed formation 
and subsequent analysis. 
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3.2.3 Bacterial strains 
E. coli DH5a was used for plasmid manipulation and maintenance. 
Agrobactehum tumefaciens LBA4404/pAL4404 (Hoekema et al., 1983) was used for 
tobacco transformation. 
3.2.4 Codon modification of IGF-I and IGFBP-3 cDNAs 
Differences in codon usage among organisms can lead to a variety of problems 
in heterologous gene expression. As target genes are usually not originated from 
plant, therefore whether the target gene is translatable in the desired plant has always 
caused problem in developing the expression system. Different studies have 
showed that codon usage biases are strongly correlated with gene expression levels. 
Highly expressed genes preferentially use a subset of codons called "optimal" codons 
(Moriyama and Powell, 1997). Moreover, these optimal codons correspond to the 
most abundant tRNAs (Moriyama and Powell, 1997), leading to enhanced translation 
accuracy and efficiency (Marais et al., 2001). 
The DNA sequences of the human IGF-I (Jansen et al., 1983; Figure 3- 1) and 
IGFBP-3 (Wood et al, 1988; Figure 3- 2) were modified based on the preferred 
codons used in two seed storage proteins. Codon usage of lysine-rich protein (LRP) 
from winged bean and methionine-rich 2S albumin (PN2S) from Paradise nut (Table 
3- 1) were chosen as the bases for modification because high expression and stable 
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accumulation (3-10% and 3-15% of total extractable seed proteins for LRP and PN2S, 
respectively) in transgenic Arahidopsis was observed in previous studies (Cheng, 
1999; Chen, 2000). 
The modified IGF-I (Figure 3- 3) and IGFBP-3 (Figure 3- 4) genes, encoding 
the same amino acid sequences (Figures 3- 5 and 3- 6) as the original ones, were 
synthesized and cloned in cloning vectors (Figure 3- 7) by MWG Biotech Inc. The 
plasmid with the modified IGF-I cDNA was named pIGF-I while that with the 
modified IGFBP-3 as pIGFBP-3. The change of codons of IGF-I and IGFBP-3 







Figure 3- 1 Nucleotide sequence of the human IGF-I cDNA 
The length of the human IGF-1 cDNA is 213 bp. The stop (TAG) 
















Figure 3- 2 Nucleotide sequence of the human IGFBP-3 cDNA 
The length of the human IGFBP-3 cDNA is 795 bp. The stop (TAG) 
codon is shaded. 
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Table 3-1 Summary of codon preference prioritized based 
on the LRP and PN2S sequences 
A . -J Triplet 
Ammo acid  
ist priority 2"' priority priority 
Phe TTT / TTC - “ 
Leu ^ T T G CTT /CTG 
. He ATT/ATC ATA -
Met ATG - ^ 
Val GTT G T G -
^ A G T / TCT / T C C T ^ 
P r o C C T / C C C C C A C C G 
Thr A^ A C A A C T 
Ala OT G C C -
TAC - : 
^ C A C - ； 
G ^ C A A C A G -
^ A A T / A A C - _ 
^ A A A / A A G - ^ 
^ GAT G A C ^ 
^ G A G G A A -
^ T G C - . 
Trp T G G - ^ 
Arg CGG/AGA/AGG C ^ : 
^ G G C / G G A G G T G G G 







Figure 3- 3 Nucleotide sequence of the modified IGF-I cDNA 
The length of the modified IGF-I cDNA is 213 bp. The stop (TGA) 
















Figure 3- 4 Nucleotide sequence of the modified IGFBP-3 cDNA 
The length of the modified IGFBP-3 cDNA is 795 bp. The stop 




Figure 3- 5 Deduced amino acid sequence of IGF-I , 






Figure 3- 6 Deduced amino acid sequence of IGFBP-3 




Kpnl, AccI AccI, BamHI, Hindlll 
CIGF-I or IGFBP-3 cDNA 
pIGF-l or I G F B ^ ^ ^ ^ ^ ^ ^ ^ ^ 
Figure 3- 7 Construct containing the modified IGF-I (pIGF-I) or IGFBP-3 
(pIGFBP-3) cDNA 
The modified IGF-I (pIGF-I) or IGFBP-3 (pIGFBP-3) cDNA was 
synthesized and cloned in cloning vector by MWG Biotechnology 
Company. There were restriction enzyme sites at both the 5' (Kpnl 
and AccI) and the 3’ (AccI, BamHI and Hindlll) ends of the cDNA to 
facilitate further cloning. 
‘-
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3.2.5 Transient assay to study IGF-I or IGFBP-3 translatability 
It is time consuming to produce mature transgenic lines for analysis of the 
translatability of the target gene in plants. Recently new and rapid methods has 
been employed to test genes translatability in plants, including particle bombardment 
of mRNA into plant cell cultures (Walker et al, 1990) and DNA into wheat (Ortiz et 
al., 1997). 
In this study, codon modified IGF-I or IGFBP-3 cDNA was fused with GUS 
gene and directly delivered into plants using particle bombardment method for 
analysis of its translatability in plants. 
3.2.5.1 Construction of chimeric genes for particle bombardment 
pBI221 (Clontech) is a plant expression vector that contains the CaMV 35S 
promoter, the GUS gene, the NOS terminator and the ampicillin resistant gene. 
Firstly，the start codon of the GUS gene was deleted by site-directed mutagenesis via 
PCR with specific primers (Figure 3- 8). The IGF-I or IGFBP-3 cDNA was 
amplified by PCR with another sets of primer (Figure 3- 9) and fused with the 
beginning of the GUS gene at BamHI and Smal sites (Figure 3- 10). The sequences 
of chimeric gene were confirmed by sequencing as described in section 3.2.7. 
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Primers for the amplification of the GUS gene without ATG start codon: 
No ATG GUS: 5' GGGTCTTTTACGTCCTGTAGAAAC 
Right All GUS: 5' ATATGAGCTCGGTGCAATTCCCCA 
Figure 3- 8 Primer sequences for the amplification of GUS gene without ATG 
start codon 
Primers were designed for removal of ATG in the GUS gene. The 
Smal and Sad sites are underlined. 
(A) Primers for the amplification of IGF-I: 
Gun IGF-I Left: 5' CGGGATCCATGGGTCCTGAGACCCTC 
Gun IGF-I Right: 5' GGGGAAGCGGACTTGGCAGGCTT 
(B) Primers for the amplification of IGFBP-3: 
Gun BP-3 Left: 5' CGGGATCCATGGGAGCTAGCTCTGGA 
Gun BP-3 Right: 5' GGGGACTTGCTCTGCATGCTGTA 
Figure 3- 9 Primer sequences for the amplification of IGF-I and IGFBP-3 
、cDNA for the GUS fusion constructs for particle bombardment 
Two sets of primer were designed for the GUS fusion constructs for 
particle bombardment (A for IGF-I and B for IGFBP-3). The 
BamHI and Smal sites are underlined. 
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BamHI, Smal 
C IGF-I or q 
IGFBP-3 cDNA 」 ^ U S 、 
BamHI & Smal 
，r 
^ . BamHI Smal 
BamHI Smal 
IGF-I or 35Spr。 GUS 




ocQ IGF-I or 
IGFBP-3 CDNA b U b 
~pBI221/35S/IGF-lor I G F B P - 3 : : G U S ^ 
* 
Figure 3- 10 Construction of chimeric gene pBI221/35S/IGF-I or 
IGFBP-3::GUS 
The IGF-I or IGFBP-3 cDNA was fused with the GUS gene without 
the start codon (ATG) at BamHI and Smal sites in pBI221 and ready 
for bombardment to test for the expression efficiency. 
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3.2.5.2 Particle bombardment of GUS fusion constructs 
Young tobacco leaves and soybean cotyledons were cut into 0.5 cm X 0.5 cm 
and arranged in the center of the supporting medium (MS salts (2.2 g/L, Sigma 
M-5519), 2% sucrose, 0.8% agar (Sigma), pH 5.7) to form an area of 2 cm X 2 cm. 
Then, the samples were bombarded using the biolistic PDS-lOOO/He system 
(Bio-Rad) according to the procedures described by Sidorov et al. (1999). 
Sixty mg of gold particles (1.0 um in diameter) were washed and vortex with 1 
ml 70% ethanol for 5 minutes in an eppendorf tube. Then it was allowed to stand 
for 15 minutes and centrifuged for 5 seconds. The pellet was saved and rinsed three 
times with 1 ml sterile distilled water. The gold particles were resuspended in 
concentration to 60 mg/ml of 50% glycerol. For bombardment, 5 ul of plasmid 
DNA (1 ug/ul), 50 ul of 2.5 M CaCh and 20 ul of 0.1 M spermidine were added into 
50 ul (3 mg) of gold particles and vortex vigorously for 2 minutes. The mixture 
was settled for 1 minute and spun for 5 seconds. The supernatant was discarded 
and the pellet was washed with 140 ul of 70% EtOH. 70% EtOH was discarded and 
replaced with 100% EtOH without disturbing the pellet. Then 100% EtOH was 
removed. Finally, the pellet was resuspended in 48 ul of 100% EtOH. For each 
bombardment, 0.5 mg gold particles and 1 ug of plasmid DNA were pipetted onto the 
macrocarrier and allowed to dry. The samples were bombarded twice at 1100 psi 
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Helium pressure, 27 in of Hg vacuum and the target distance was 9 cm. After 
bombardment, the samples were incubated for 24 hours in plant growth chamber and 




3.2.6 Construction of chimeric genes for tobacco transformation 
The plant-optimized modified IGF-I and IGFBP-3 cDNAs were cloned into 
vectors with different temporal and spatial expression patterns. The resulting 
chimeric genes were then cloned in the Agrobacterium binary vector pBI 121 and 
finally introduced into the tobacco plants via Agrobacterium-mt6\diiQ(\ 
transformation. 
3.2.6.1 Construction of chimeric genes with different promoters 
The modified IGF-I and IGFBP-3 cDNAs were cloned into vectors that 
contained the CaMV 35S or the phaseolin promoter only. 
3.2.6.1.1 Construction of chimeric gene with CaMV 35S promoter 
The IGF-I cDNA from pIGF-I (Figure 3- 7) was subcloned into pUC/35S (Yu, 
2001), a vector with the CaMV 35S promoter (pro) and the nopaline synthase (Nos) 
terminator (ter), through insertion between the Kpnl and BamHI sites as illustrated in 




Kpnl BamHI Kpnl BamHI 
广 IGF-I cDNA ^^^^^^ 35Spr。 P30 HQS,,, ^ ^ ^ ^ 
pIGF-l ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
Kpnl & BamHI 
1 r 
Kpnl BamHI Kpnl BamHI 








Figure 3-11 Construction of chimeric gene pUC/35S/IGF-I 
The IGF-I cDNA from pIGF-I was subcloned into pUC/35S-P30 
between the Kpnl and BamHI sites. The resulting construct, 
pUC/35S/IGF-I, contains the IGF-I cDNA sandwiched between the 
CaMV 35S promoter (35Spro) and the Nos terminator (Noster). (P30 
=T. gondii surface antigen P30) 
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3.2.6.1.2 Construction of chimeric genes with phaseolin promoter 
Phaseolin is the predominant seed storage glycoprotein of French bean 
{Phaseolus vulgaris L.). It is a globulin consisting of 3 subunit polypeptides (a, P 
and y). p-phaseolin gene was isolated by Sun et al. in 1981 and it's promoter was 
characterized by Sengupta-Gopalan et al. in 1985. Phaseolin promoter is a very 
strong seed specific promoter that can drive phaseolin expression to 50% of the total 
protein in mature French bean seeds. Since the phaseolin promoter yields strong 
and seed-specific expression, it has been utilized in expressing foreign proteins in 
plants. In previous study, up to 30% increase in methionine content was 
demonstrated in the transgenic expression of Brazil nut methionine-rich protein in 
tobacco with the use of the phaseolin promoter (Altenbach et ai, 1989). The 
phaseolin promoter has also been exploited in the expression of malaria surface 
antigen in tobacco and Arabidopsis (Ng, 2001; Lau, 2002); Toxoplasma gondii 
surface antigen P30 in tobacco (Yu, 2001) and white shrimp molt-inhibiting hormone 
in tobacco (Fong, 2001). 
The vector pTZ/Phas (Yu, 2001)，containing the phaseolin promoter and the 
phaseolin terminator, was used. The P30 gene was excised by AccI and replaced by 
the IGF-I or IGFBP-3 cDNAto form pTZ/Phas/IGF-I or IGFBP-3 (Figure 3- 12). 
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AccI AccI Acd AccI 
^ ^ IGF-I or IGFBP-3 cDNA 广 PhaSp⑴ P30 PhaSte^ ^^ ^^ ^^ ^^ ^ 
AccI 
1 r 
AccI AccI AccI AccI 
IGF-I or IGFBP-3 cDNA 厂 PhaSp,。 PhaSte^ ^^^^^^^ 
Ligation 
AccI AccI 
PhaSpro IGF-I or IGFBP-3 cDNA 
/ \ 
pTZ/Phas/IGF-l or IGFBP-3 
* 
» 
Figure 3-12 Construction of chimeric gene pTZ/Phas/IGF-I or IGFBP-3 
The IGF-I or IGFBP-3 insert was excised from pIGF-I or pIGFBP-3 
using AccI and subcloned into pTZ/Phas. The resulting construct, 
pTZ/Phas/IGF-I or IGFBP-3, contains the phaseolin promoter (PhaSpro) 
and terminator (Phaster) flanking the IGF-I or IGFBP-3 cDNA. (P30 
=T. gondii surface antigen P30) 
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3.2.6.2 Construction of fusion constructs 
Two kinds of fusion construct were made. The IGF-I or IGFBP-3 cDNA was 
fused either at the beginning of the P-glucuronidase (GUS) gene or into the middle of 
the lysine-rich protein (LRP) gene. 
3.2.6.2.1 Construction of GUS fusion constructs 
Plasmid pBI 121 (Clontech) is a plant expression vector which contains the 
GUS gene driven by CaMV 35S promoter. The IGF-I or IGFBP-3 cDNA was 
cloned at the beginning of the GUS gene. 
The IGF-I and IGFBP-3 cDNAs were amplified by PGR and a 5' Xbal site and 
a 3’ Smal site were introduced. The primer sets were used 35IGFL, 35IGFR (for 
IGF-I) and 35BP-3L, 35BP-3R (for IGFBP-3) as shown in Figure 3- 13. The 
templates used were pIGF-1 and pIGFBP-3. A 25 ul reaction mix containing 100 
ng of DNA template, IX Pfu buffer (Strategene), 2 mM MgCb, 0.2 mM dNTPs, 1 
uM 5' primer, 1 uM 3’ primers 1.25 units Pfu DNA polymerase (Strategene) was 
prepared for each of the target genes. The PGR conditions were as follows: 94°C 
for 5 minutes, then 25 cycles of 94°C for 30 seconds, 53°C for 1 minute and 72。C for > 
1 minute, followed by 1 cycle of 72°C for 7 minutes. The PGR products were 
digested by Xbal and Smal and ligated into pBI 121 to form pBI121/35S/IGF-I or 
IGFBP-3::GUS (Figure 3- 14). 
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(A) Primers for the amplification of IGF-I: 
35IGFL: 5' GCTCTAGAGCATGGGTCCTGAGACC 
35IGFR: 5' CTCAAGCGGACTTGGCAGGCTT 
(B) Primers for the amplification of IGFBP-3: 
35BP-3L: y GCTCTAGAGCATGGGAGCTAGCTCTGGAGG 
35BP-3R: 5' CTCACTTGCTCTGCATGCTGTA 
Figure 3-13 Primer sequences for the amplification of IGF-I and IGFBP-3 
cDNAs for the GUS fusion constructs 
Two sets of primer were designed for the GUS fusion constructs (A 
for IGF-I and B for IGFBP-3). The start (ATG) and stop (TGA) are 





^ Xbal and Smal 
Z IGF-I or IGFBP-3 cDNA \ ^ 35Spro GUS NOSter \ 
( ( \ 
AccI 
Xbal Smal Xbal Smal 
IGF-I or IGFBP-3 cDNA 35Spr。 GUS NOSter 
( P B I ^ ) 
Ligation 
Xbal Smal 
35Spro IGF-I or IGFBP-3 cDNA GUS NO、r 
/ \ 
pBI 121/35S/IGRI or IGFBP-3::GUS 
Figure 3-14 Construction of chimeric gene pBI 121/35S/IGF-I or 
IGFBP-3::GUS 
A 5' Xbal and a 3’ Smal sites were added to the IGF-I or IGFBP-3 
cDNA by PGR. After Xbal and Smal digestion, this PGR product 
was cloned in pBI 121. The resulting construct, pBI 121/35S/IGF-I 
or IGFBP-3::GUS，contained the target gene inserted in front of the 
GUS gene. 
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3.2.6.2.2 Construction of LRP fusion constructs 
Lysine-rich protein (LRP) is a seed protein with high lysine content from 
winged bean {Psophocarpus tetragonolobus). Because of its high amount of lysine, 
LRP was cloned and then expressed in different plants for nutrition enhancement. It 
was demonstrated that LRP, when driven by the seed-specific phaseolin promoter, 
could be highly expressed (up to 8-10% as the total protein) in transgenic 
Arabidopsis (Cheng, 1999). In another study, LRP (driven by the glutelin (Gtl) 
promoter) was transferred and highly expressed in the endosperm of transgenic rice. 
The stable accumulation of LRP in mature rice seeds amounted to 12% of the total 
soluble seed protein (Liu, 2002). According to its high expression and stable 
accumulation in previous studies, it was used as a fusion backbone to enhance IGF-I 
and IGFBP-3 expression in the transgenic tobacco. The IGF-I or IGFBP-3 cDNA 
was inserted into the mid region (at the 46【卜 amino acid) of the LRP gene, so as to 
minimize its effect on the overall conformation of the fusion protein. The fusion 
gene was driven by the phaseolin promoter. 
The target genes were PGR amplified with specific primers that introduce a 5' 
and a 3’ Ncol sites plus an enterokinase (EK) recognition sequence. For amplifying 
IGF-I cDNA, primers LEFT IGF-I FU and RIGHT IGF-I FU (Figure 3- 15) were 
employed, using pIGF-I (Figure 3- 7). For amplifying IGFBP-3 cDNA, primers 
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LEFT BP-3 FU and RIGHT BP-3 (Figure 3- 15) were employed, using pIGFBP-3 
(Figure 3-7) instead. The PCR reactions and conditions were the same as described 
in section 3.2.6.2.1. The PCR products were digested with Ncol and cloned into 
pBKII/LRP12A (constructed by Lo, Dept. of Biology, CUHK). Finally, the fusion 
genes were excised by AccI and cloned into the vector pTZ/phas to form 
pTZ/Phas/LRPi::IGF-I or IGFBP-3::LRP2 (Figure 3- 16). 
I 
52 
(A) Primers for the amplification of IGF-I: 
LEFT IGF-I FU: 5' AGTCTACCATGGGTCCTGAGACCCTC 
RIGHT IGF-工 FU: 5' CATGCCATGGCCTTATCGTCATCGTC 
AGCGGACTTGGCAGGCTTG 
(B) Primers for the amplification of IGFBP-3: 
LEFT BP-3 FU: 5' AGTCTACCATGGGAGCTAGCTCT'GGAG 
RIGHT BP-3 FU: 5' CATGCCATGGCCTTATCGTCATCGTC 
CTTGCTCTGCATGCTGTAGC 
Figure 3-15 Primer sequences for the amplification of IGF-I and IGFBP-3 
cDNAs for the LRP fusion constructs 
Two sets of primer were designed for the LRP fusion constructs (A for 






^ ^ _ • Ncol 
IGF-I or L I 
IGFBP-3 cDNA LRPI EK LRP 
vcf^ .Cj：：；：^ 
Ncol y r 
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么 , H EK EK LRP2 
ACCI L _ _ — — ： ： ^ _ _ _ _ L I Acci 
pBKII/LRP12::IGF-l or IGFBP-3 
AccI 
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AccI AccI AccI AccI 
LRP1 EK IGF'BP-IcDNA EK 」 P h a S p r o 




PhaSpro LRP1 EK ,gfbP3°dna [K L R P 2 Phas,,, 
pTZ/Phas/LRP1::IGF-l or IGFBP-3::LRP2 
Figure 3-16 Construction of chimeric gene pTZ/Phas/LRPl::IGF-I or 
IGFBP-3: :LRP2 
A 5' Ncol, a 3’ EK and a 3’ Ncol sites were added to the IGF-I or 
IGFBP-3 cDNA by PGR. After Ncol digestion, this PGR product 
‘ was cloned in pBKII/LRP12A to form pBKII/LRP12::IGF-I or 
‘IGFBP-3. The LRP/IGF-I or IGFBP-3 fusion gene was excised and 
cloned into pTZ/Phas. The resulting construct, 
pTZ/Phas/LRPl::IGF-I or IGFBP-3::LRP2, contained the target gene 
inserted in between the LRP gene. 
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3.2.6.3 Construction of phaseolin targeting constructs 
In developing bean cotyledons, phaseolin is transported to the protein storage 
vacuoles (PSV). This trimming event occurs at the C-terminus and involves four 
amino acids (AFVY) that are necessary for vacuolar sorting (Frigerio et al., 2001). 
When the C-terminal AFVY was deleted, the phaseolin protein was secreted outside 
of the cells. These results indicated that the phaseolin C-terminal AFVY involved 
the targeting signal in the cells. Previous studies by Lau (2002) using phaseolin 
promoter and the AFVY targeting signal was successful in driving the expression of 
Malaria surface antigen in both Arabidopsis and tobacco plants. An estimated 
expression level of 0.2% total soluble protein was attained. The protein was shown 
to be targeted and accumulated in the protein-storage vacuoles (PSV) in transgenic 
tobacco seeds. The natural antigenicity of the recombinant protein from 
Arabidopsis was also retained as shown by immunoblotting using human serum. 
Phaseolin targeting constructs contains phaseolin promoter and phaseolin signal 
peptide, with or without the C-terminal AFVY-targeting signal, were made. 
3.2.6.3.1 Construction of phaseolin targeting constructs without AFVY 
Primers (Figure 3- 17) were designed to introduce a 5' Ndel site and 3’ AccI site 
to the target genes. The PCR reactions and the conditions were described in section 
3.2.6.2.1. The PCR products were first cloned into pGEM®-T vector (Promega). 
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The target gene was then digested with Ndel and AccI and cloned into 
pBKyPhas/SP/MP42 (Lau, 2003) to form pBK/Phas/SP::IGF-I or IGFBP-3 (Figure 3-
18). 
(A) Primers for the amplification of IGF-I: 
IGF-I Left: 5' CATATGCCACCGGTCCTGAGACCCTCTGCGG 
ACCIGF: 5' GAAGTATACTCAAGCGGACTT 
(B) Primers for the amplification of IGFBP-3: 
Left BP-3: 5' CATArGCCACCGGAGCTAGCTCTGGAGGTTT 
ACCBP3: 5' GAAGTATACTCACTTGCTCTGC 
Figure 3-17 Primer sequences for the amplification of IGF-I and IGFBP-3 
cDNAs for the phaseolin targeting constructs without AFVY 
Two sets of primer were designed for the phaseolin targeting 
constructs without AFVY (A for IGF-I and B for IGFBP-3). The 
stop codon (TGA) is shaded. The Ndel and AccI sites are underlined. 






^ ^ ^ IGFBP-3 cDNA ^ ^ ^ 
广 一 \ 、 
- P G R 
• 
Ndel AccI T 了 
IGF-I or 
IGFBP-3 cDNA / \ 
^ Ligation 
Ndel AccI Ndel AccI 
IGF-I or r r 
^ ^ ^ IGFBP-3 CDNA PhaSpro SP MP42 Phas,,, 
I pGEM®-T/IGF-l or IGFBP-3 ) i pBK/Phas/SP::MP42 ) 
^ ^ ^ ^ ^ 
各 Ndel, AccI 
58 
Ndel AccI Ndel AccI 
IGF-I or 
IGFBP-3 cDNA 沖 a S p r 。 P h a S t e r 
Ligation 
Ndel AccI 
Phaspro SP ,GFBP.3°DNA PhaSter 
/ ^ ^ ^ 
Figure 3-18 Construction of chimeric gene pBK/Phas/SP::IGF-I or IGFBP-3 
A 5' Ndel and a 3' AccI sites were added to the IGF-I or IGFBP-3 
cDNA by PCR. This PCR product was first cloned into pGEM®-T 
vector. After Ndel and AccI digestion, the target gene was excised 
and cloned in pBK/Phas/SP. The resulting construct, 
‘ I pBK/Phas/SP::IGF-I or IGFBP-3, contained the phaseolin signal 
peptide. .. 
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3.2.6.3.2 Construction of phaseolin targeting constructs with AFVY 
As described in section 3.2.6.3.1, primers (Figure 3- 19) were designed to 
introduce a 5' Ndel site and 3’ AFVY targeting sequence (AccI site is the ‘‘VY,,) to 
the target genes. The PCR reactions and the conditions were described in section 
3.2.6.2.1. The PCR products were first cloned into pGEM(B)-T vector (Promega). 
The target gene was then digested with Ndel and AccI, and cloned into 
pBKyPhas/SP/MP42 (Lau, 2003) to form pBK/Phas/SP::IGF-I or IGFBP-3::AFVY 
(Figure 3- 20). 
» 
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(A) Primers for the amplification of IGF-I: 
IGF-工 Left: y CATATGCCACCGGTCCTGAGACCCTCTGCGG 
IGF-I Right: 5' GTATACAAATGCAGCGGACTTGGCAGGCTTGAG 
(B) Primers for the amplification of IGFBP-3: 
Left BP-3: 5' CArATGCCACCGGAGCTAGCTCTGGAGGTTT 
Right BP-3: 5' GTATACAAATGCCTTGCTCTGCAGGCTGTAGCA 
Figure 3- 19 Primer sequences for the amplification of IGF-I and IGFBP-3 
cDNAs for the phaseolin targeting constructs with AFVY 
Two sets of primer were designed for the phaseolin targeting 
constructs with AFVY (A for IGF-I and B for IGFBP-3). The AFVY 
sequences are shaded. The Ndel and AccI sites are underlined. 
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V 、 
Figure 3- 20 Construction of chimeric gene pBK/Phas/SP::IGF-I or 
IGFBP-3:: AFVY 
‘ A 5' Ndel site and a 3' AFVY targeting sequence (AccI site is the 
> 
"VY") were added to the IGF-I or IGFBP-3 cDNA by PGR. This 
PCR product was first cloned into pGEM(E)-T vector. After Ndel 
and AccI digestion, the target gene was excised and cloned in 
pBK/Phas/SP. The resulting construct, pBK/Phas/SP::IGF-I or 
IGFBP-3::AFVY, contained both the phaseolin signal peptide and 
AFVY targeting sequence. 
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3.2.6.4 Cloning of chimeric genes into Agrobacterium binary vector pBI 121 
All chimeric gene constructs (from sections 3.2.6.1 to 3.2.6.3, except pBI 
121/35S/IGF-I or IGFBP-3::GUS in section 3.2.6.2.1) were cut with Hindlll to 
release the gene expression cassettes and ligated into the Agrobacterium binary 
vector pBI 121 (Figure 3- 21). The pBI 121 vector contains the neomycin 
phosphotransferase II (NPTII) antibiotic selectable marker and p-glucuronidase 
(GUS) protein color reporter genes. Totally, eleven chimeric constructs were 






NOSpr� NPTII NOSter 35S GUS mS,,, 
y \ 
I pBI 121 j 
Figure 3-21 Cloning of chimeric genes into Agrobacterium binary vector pBI 
121 
The promoter-target gene-terminator cassette (from sections 3.2.6.1 to 
3.2.6.3) was excised using Hindlll and inserted into the Hindlll site of 
Agrobacterium binary vector pBI 121. The resulting construct 
contains the cassette sandwiched between neomycin 
phosphotransferase II (NPTII) selectable marker and P-glucuronidase 




3.2.7 Confirmation of sequencing fidelity of chimeric genes 
Cycle sequencing using ABI PRISM® dRhodamine Terminator cycle sequencing 
kit (Applied Biosystems) and ABI PRISM® 3100 Genetic Analyzer (Applied 
Biosystems) was carried out as described in the user manual to confirm the sequence 
fidelity of the chimeric genes. 
3.2.8 Transformation of Agrobacterium by electroporation 
The chimeric genes in pBI 121 expression vectors were transformed into 
Agrobacterium tumefaciens LBA4404/pAL4404 electroporation (Sambrook et al, 
1989). 
An aliquot of 40 ul of Agrobacterium LBA4404 competent cells was thawed on 
ice and mixed with 0.5 ug of plasmid DNA. The cell-DNA mixture was transferred 
to the electroporation cuvette (Bio-Rad) and subjected to a pulse of 25 fiF, 2.5 kV 
and 600 ohms in the Gene Pulser (Bio-Rad). After discharge, 1 ml of SOC medium 
(2% bacto-tryptone, 0.5% bacto-yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgS04 and 20 mM glucose) was added to the cuvette. The cell suspension was 
» 
incubated at 28°C for 4 hours： Then, the bacterial culture was spread on LB agar 
plates (10 g/L NaCl, 10 g/L bacto-tryptone, 5 g/L yeast extract and 15 g/L bacto-agar) 
supplemented with 50 mg/L kanamycin and 25 mg/L streptomycin and incubated at 
28°C for 2 days. When the bacterial colonies were formed, PCR using specific 
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primers was performed to check for successful transformation. 
3.2.9 Transformation of tobacco 
A single colony of Agrobacterium LBA4404 containing the pBI 121 expression 
cassette was cultured in 3 ml of LB medium (10 g/L bacto-tryptone, 5 g/L 
bacto-yeast extract and 10 g/L NaCl) with 50 mg/L kanamycin and 25 mg/L 
streptomycin and shaken at 28°C for 20 hours to reach OD62o〉l. The bacterium 
was centrifuged at 5800 rpm at room temperature for 10 minutes. The pellet was 
washed with 5 ml of inoculation liquid medium (4.4 g/L MS salts (Sigma M-5519), 
30 g/L sucrose and 100 mM acetosyringone (AS), pH 5.7) and finally resuspended in 
3 ml of inoculation liquid medium. 
Wild type tobacco leaves were cut into small pieces of about 0.5 x 0.5 cm�. 
The leaf discs were submerged in Agrobacterium culture (lOx dilutions with 
inoculation liquid medium) for 10 minutes, and then transferred to the sterile filter 
paper for drying. The explants were placed on co-culture medium (42.4 g/L MS 
medium (Sigma MS-9274) and 100 mM AS, pH 5.7) at 25°C for 2 days. 
I 
3.2.10 Selection and regeneration of transgenic tobacco 
After co-cultivation for 2 days, the leaf discs were transferred to selection 
medium (44.23 g/L MS medium, 1 mg/L N^-benzyladenine (BA), 0.1 mg/L (lAA), 
500 mg/L carbenicillin (Car) and 100 mg/L kanamycin (Kan), pH 5.7) every 2 weeks 
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for shoot regeneration. About 6 weeks, the regenerated shoots were cut off and 
transferred to rooting medium (44.23 g/L MS medium, pH 5.7) for rooting. 
Transgenic tobacco plantlets were finally transferred to soil and grown in the 
greenhouse. 
3.2.11 GUS assay 
GUS assay was performed as described by Jefferson et al (1987). Samples 
after bombardment as described in section 3.2.5.2 or regenerated tobacco leaves were 
incubated in GUS staining solution (100 mM sodium phosphate buffer, pH 7.0, 0.1% 
Triton X-100，1 mM EDTA, 0.5 mM K3.Fe(CN)6, 0.05 mM K4.Fe(CN)6 and 0.5 
mg/ml 5-bromo-4-chloro-3-indolyl-P-glucuronic acid (X-Glu)) at 37°C for 1-2 days. 
Chlorophyll background was removed by soaking in 70% ethanol (EtOH). 
3.2.12 Extraction of leaf genomic DNA 
Leaf genomic DNA was extracted by the Cetyltrimethylammonium bromide 
(CTAB) method (Doyle et al., 1990). Three pieces of leaf discs (cut by pressing 
tobacco leaf against the cap of an 1.5 ml microcentrifuge tube) were ground in 600 ul 
i 
of 2% CTAB buffer (0.1 M Tris-HCl, pH 8.0, 1.4 M NaCl, 20 mM EDTA, 2% CTAB 
and 0.2% p-mercaptoethanol (P-mer)) with a glass rod in the presence of sterile sand. 
The homogenate was incubated at 60°C for 40 minutes with periodic mixing. Half 
an ml of chloroform/ isoamyl alcohol (24:1, v/v) was added, mixed and centrifuged 
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at 14,000 rpm at 4°C for 15 minutes. The upper aqueous layer was transferred to a 
new tube and mixed with 500 ul of cold isopropanol. The mixture was kept at 
-20°C for 1 hour and then centrifuged at 14,000 rpm at 4°C for 30 minutes. The 
pellet was washed with 70% EtOH. Dried pellet was dissolved in 50 ul of ddHiO. 
The quantity and quality of DNA were checked by OD260 and OD280 measurements 
or by gel electrophoresis. 
3.2.13 PCR of genomic DNA 
The purified genomic DNA was used as template, and PCR was performed to 
detect the presence of the transgene in regenerated tobacco. The PCR reactions and 
conditions were performed according to section 3.2.4.3.1, but 500 ng of genomic 
DNA and 2.5 units of Taq DNA polymerase (Promega) were used instead. Ten ul of 
PCR product was used for 1% agarose gel electrophoresis. 
3.2.14 Synthesis of DIG-labeled double-stranded DNA probe 
Double strand DIG-labeled DNA probes (IGF-I or IGFBP-3) were prepared 
using DIG DNA labeling Kit (Roche) by PCR. The template DNA was used 
pIGF-1 or pIGFBP-3 (Figure 3- 7) and the primers used were 35IGFL and 35IGFR 
for IGF-I or 35BP-3L and 35BP-3R for IGFBP-3 (Figure 3- 10). The labeling 
efficiency of the probe was estimated by a spot test using DIG-labeled control DNA 
as described in the manual for DIG DNA Labeling Kit (Roche). 
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3.2.15 Southern blot analysis 
Fifteen ug of genomic DNA was digested overnight with Hindlll or BamHI, 
separated on 0.8% agarose gel at 70 V for 3 hours and then transferred to positively 
charged nylon membrane (Roche) using the VacuGeneXL Vacuum blotting System 
(Pharmacia Biotech). Hybridization and detection was carried out according to the 
method described in the DIG Nucleic Acid Detection Kit (Roche). Double strand 
DIG-labeled DNA probes (IGF-I and IGFBP-3) were prepared as described in 
section 3.2.12. The probes were heated to denature at 99°C before use. 
3.2.16 Extraction of total RNA from leaves or developing seeds 
Leaf total RNA was extracted from transgenic plants transformed with the IGF-I 
or IGFBP-3 constructs containing the constitutive CaMV 35S promoter. For 
transgenic plants harboring seed-specific phaseolin promoter constructs, total RNA 
was extracted from developing seeds collected 20 day-after-flower (DAF). A 
small-scale RNA extraction protocol of Altenbach et al. (1989) was used. 
About 0.3 g of plant tissue was ground into powder under liquid nitrogen with a 
mortar and pestle. After adding 0.3 ml of RNA extraction buffer (0.1 M LiCl, O.IM 
Tris-HCl, pH 8.0’ 0.1 M EDTA and 1% SDS) and 0.3 ml of phenol, the sample was 
heated at 55°C for 15 minutes. An additional 0.6 ml of chloroform/ isoamyl alcohol 
(24:1, v/v) was mixed with the sample and the mixture was centrifuged at 10,000 
70 
rpm for 5 minutes. The upper aqueous phase was transferred to a new tube, mixed 
with an equal volume of 4 M LiCl and kept at 4°C for 2 hours. The mixture was 
then centrifuged at 14,000 rpm at 4°C for 10 minutes. The pellet was washed with 
0.2 ml of 2 M LiCl and centrifuged at 14,000 rpm at 4°C for 10 minutes. After 
centrifugation, the pellet was resuspended in 0.25 ml of diethylpyrocarbonate 
(DEPC)-treated water and 25 i^l of 3 M DEPC-treated sodium acetate (pH 5.0) 
before mixing with 0.5 ml of cold absolute EtOH and kept at -20°C for 2 hours. 
The mixture was centrifuged again at 14,000 rpm at 4°C for 10 minutes. The pellet 
was washed twice with 70% EtOH, allowed to air-dry and finally dissolved in 20 ul 
of DEPC-treated water. The quantity and quality of RNA were checked by OD260 
and OD280 measurements or by agarose/formaldehyde gel electrophoresis. 
3.2.17 Northern blot analysis 
Five ug of total RNA was separated in 0.8% agarose/formaldehyde gel at 70 V 
for 1.5 hours and transferred to a positively charged nylon membrane (Roche) using 
the VacuGeneXL Vacuum blotting System (Pharmacia Biotech). Hybridization and 
detection were carried out according to the method described in the DIG Nucleic 
Acid Detection Kit (Roche) as mentioned in section 3.2.13. 
3.2.18 Extraction of total protein 
Total seed protein was extracted from mature seed of transgenic tobacco. 
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Seeds (0.02 g) were ground in liquid nitrogen and mixed with 300 ul of SDS-Tris 
buffer (7.75% SDS, 0.125 M Tris-HCl, pH7.0, 10% P-mercaptoethanol (P-mer) and 
1 tablet per 50 ml of protease inhibitor cocktail (Roche)). The homogenate was 
centrifuged at 15,000 rpm at 4°C for 10 minutes. The upper supernatant was 
transferred to a new eppendorf tube. The quantity of seed protein was determined 
by the bicinochoninic acid (BCA) method and bovine serum albumin (BSA) was 
used as standard. 
3.2.19 Tricine SDS-PAGE 
Fifty ug of total seed protein was mixed with 2X sample loading buffer (0.0625 
M Tris-HCl, pH 6.8, 2% SDS, 1% P-mer, 10% glycerol and 0.01% bromophenol 
blue), heated at 99°C for 10 minutes. The samples were resolved in 17.5% 
SDS-PAGE in electrode buffer (0.025 M Tris, 0.19 M glycine and 0.1% SDS, pH 8.3) 
at 50V for 30 minutes and then lOOV for 1.5 hours. After electrophoresis, the gel 
was stained in Coomassie blue solution (0.25% Coomassie brilliant blue R-250, 50% 
methanol and 10% glacial acetic acid) for at least 30 minutes and destained in 
* 
destaining solution (10% glacial acetic acid and 50% methanol). 
3.2.20 Western blot analysis 
The protein samples (in the gel) were blotted onto PVDF membrane (Bio-Rad) 
using Mini Trans-Blot cell (Bio-Rad), and then transferred in the Towbin buffer (48 
72 
mM Tris, 39 mM Glycine and 20% methanol) at 100 V for 90 minutes. The blotted 
membrane was first blocked in blocking solution for 1 hour, incubated in the primary 
polyclonal antibody (anti-human IGF-I or anti-human IGFBP-3 from Santa Cruz) at 
1:200 dilution and then in AP-conjugated anti-rabbit antibody (Bio-Rad) at 1:3000 
dilution. Finally the blot was subjected to non-radioactive detection with 
chemiluminescent Starlight^^ Substrate (ICN) as described in the manual of 
AuroraTM Western Blot Chemiluminescent Detection System (ICN). 
3.2.21 Enterokinase digestion of fusion protein 
Total seed proteins (150 ug) from transgenic plants with LRP fusion constructs 
were digested with 0.2 unit of Enterokinase (Novagen) at 20°C for 2, 4 and 6 hours. 
The digested samples were mixed with 2X sample loading buffer. Tricine 




Chapter 4 Results 
4.1 Particle bombardment for transient assay 
The IGF-I or IGFBP-3 cDNA was fused with the GUS gene for particle 
bombardment to explore the codon usage of translation in plants. If the IGF-I or 
IGFBP-3 sequence could be read through and continued into the GUS gene, the GUS 
could be expressed. 
4.1.1 Construction of GUS fusion genes for particle bombardment 
Using PCR technique, the start codon (ATG) of the GUS gene in the vector 
pBI221 was deleted and resulted in pBI221/noATG. The IGF-I or IGFBP-3 cDNA 
was fused with pBI221/noATG at BamHI and Smal sites as described in section 
3.2.5.1, resulting in pBI221/35S/IGF-I::GUS (221IG) or pBI221/35S/IGFBP-3::GUS 
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Figure 4- 1 Restriction enzyme digestion of chimeric constructs 
for particle bombardment 
pBI221, pBI221/35S/IGF-I or IGFBP-3::GUS plasmid DNA were 
digested with BamHI and Smal. The samples were separated on 
0.8% agarose gel. 
Lane 1: pBI221/35S/IGF-I::GUS clone 1 ； 
Lane 2: pBI221/35S/IGF-I::GUS clone 2; 
Lane 3: pBI221/35S/IGFBP-3::GUS clone 1 ； 
Lane 4: pBI221/35S/IGFBP-3::GUS clone 2; 
Lane 5: pBI221; 
Lane 6: 1 kb+ DNA ladder (Invitrogen). 
) 
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4.1.2 Transient expression of GUS fusion genes in soybean cotyledons 
and tobacco leaves 
Constructs pBI221/35S/IGF-I or IGFBP-3::GUS (clone 1) were used in particle 
bombardment. pBI221 and pBI221/noATG were served as the positive and the 
negative controls respectively. The experimental procedure was the same as 
described in section 3.2.5.2. After particle bombardment and GUS assay, all the 
constructs, except pBI221 (noATG), showed positive results (blue spots) on both 
soybean cotyledons and tobacco leaves (Figure 4- 2). The result indicated that the 
cDNAs of IGF-I and IGFBP-3 could be transcribed and translated in plants. 
I 
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Figure 4- 2 GUS staining of samples after particle bombardment 
* 
> Particle bombardment and GUS staining of tobacco leaves (upper 
panels) and soybean cotyledons (lower panels) were performed with 
pBI221/35S/IGF-I::GUS (panel A), pBI221 /35S/IGFBP-3:: GUS 
(panel B), pBI221 (panel C) and pBI221/noATG (panel D). 
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4.2 Construction of chimeric genes for tobacco transformation 
Six chimeric IGF-I constructs (pBI/35S/IGF-I, pBI/Phas/IGF-I, 
pBI/35S/IGF-I::GUS, pBI/Phas/LRP 1: :IGF-I: :LRP2 and pBI/Phas/SP::IGF-I, 
pBI/Phas/SP::IGF-I::AFVY, abbreviated as 31，PI, IGFu, IFu, SI and SIA respectively) 
and five chimeric IGFBP-3 constructs (pBI/Phas/IGFBP-3, pBI/35S/IGFBP-3::GUS, 
pBI/Phas/LRPl ::IGFBP-3::LRP2, pBI/Phas/SP:: IGFBP-3 and 
pBI/Phas/SP::IGFBP-3::AFVY, abbreviated as PB, BGFu, BFu, SB and SBA 
respectively) were transferred into A. tumefaciens LBA4404 through electroporation 
for tobacco transformation (Figure 4- 3). DNA sequencing and restriction enzyme 
mapping (Figure 4- 4) were performed to confirm that the transgene constructs were 
correct both in sequence and in frame. 
* 
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(A) Phas / 35S Promoter Only 
3SSpro IGF-I NOS附 pBI/35S/IGF-I (31) 
PhaSp⑴ IGF-I Phaster pBI/Phas/IGF-I (PI) 
Phasp^ IGFBP-3 Phas,,, pBLThas/IGFBP-3 (PB) 
(B) L R P Fusion 
Phasp^ LRPl EK IGF-I EK LRP2 Phas,枕 pBI/Phas/LRPl::IGF-I::LRP2 (IFu) 
Phaspr。LRPl EK IGFBP-3 EK LRP2 Phas.e, pBLThas/LRPl::IGFBP-3::LRP2 (BFu) 
(C) GUS Fusion 
3SSpro IGF-I GUS pBI/35S/IGF-I ::GUS (IGFu) 
3SSpr。 IGFBP-3 GUS NOS^,, pBI/35S/IGFBP-3::GUS (BGFu) 
(D) Protein Targeting 
PhaSp^ SP IGF-I AFVY Pha、,， pBI/Phas/SP::IGF-I::AFVY (SIA) 
Phasp^ SP IGF-I Phaster pBLThas/SP::IGF-I (SI) 
Phasp^ SP IGFBP-3 AFVY PhaSt,, pBI/Phas/SP::IGFBP-3::AFVY (SBA) 
Phasp^ SP IGFBP-3 Phas,,, pBI/Phas/SP::IGFBP-3 (SB) 
Figure 4- 3 Summary of IGF-I and IGFBP-3 constructs used for tobacco 
transformation 
All the above constructs were in the binary vector pBI 121 (described 
in sections 3.2.6.2.1 and 3.2.6.4) and used for tobacco transformation. 
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Figure 4- 4 Restriction enzyme digestion of IGF-I and IGFBP-3 constructs 
All the recombinant IGF-I and IGFBP-3 plasmid DNA were digested 
with Hindni, except pBI/35S/IGF-I or IGFBP-3::GUS in which 
Hindlll and Sad were used. The samples were separated on 0.8% 
agarose/TAE gel. 
Lane 1: pBI/35S/IGF-I (31); 2.4 kb 
Lane 2: pBI/Phas/IGF-I (PI); 2.6 kb 
Lane 3: pBI/Phas/SP::IGF-I (SI); 2.6 kb 
Lane 4: pBI/Phas/SP::IGF-I::AFVY (SIA); 2.6 kb 
Lane 5: pBI/Phas/LRPl::IGF-I::LRP2 (IFu); 3 kb 
Lane 6: pBI/35S/IGF-I::GUS (IGFu); 3.1 kb 
Lane 7: 1 kb DNA ladder (Invitrogen); 
Lane 8: pBI/Phas/IGFBP-3 (PB); 3.1 kb 
Lane 9: pBI/Phas/SP::IGFBP-3 (SB); 3.1 kb 
‘ L a n e 10: pBI/Phas/SP::IGFBP-3::AFVY (SBA) ; 3.1 kb 
Lane 11: pBI/Phas/LRPI ::IGFBP-3::LRP2 (BFu); 3.5 kb 
Lane 12: pBI/35S/IGFBP-3::GUS (BGFu). 3.6 kb 
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4.3 Tobacco transformation, selection and regeneration 
All constructs were transformed into tobacco genome via 
Agrobacterium-mQdidXQd. transformation. 
The wild type (WT) tobacco leaf were cut into small pieces and co-cultivated 
with Agrobacterium cells for 2 days. Callus developed in selection medium 
containing kanamycin about one month later. The regenerated shoots were 
transferred to rooting medium (Figure 4- 5). The transgenic tobacco plants were 





Figure 4- 5 Tobacco transformation, selection and regeneration 
Agrobacterium tumefaciens LBA4404 harboring the target construct 
was used to infect tobacco leaf. Under kanamycin selection, calli 
formed around the wounds on leaf explants (A) and differentiated into 
shoots (B) 2- 4 weeks after transformation. The regenerated shoots 
were transferred to rooting medium for rooting (C). The regenerated 
、plantlets were transferred to soil for maturation (D). 
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4.4 Detection of GUS activity 
Leaves from transformants were tested with GUS assay. Most of the leaves 
from the transformants harboring the constructs showed positive results. The leaf 
samples from transgenic plants turned deep blue while that of an untransformed plant 
(WT) remained colorless after GUS staining and chlorophyll removal (Figure 4- 6). 
The positive result from GUS assay and the selection from kanamycin implied that 
the target gene was inserted into the plant genome (the target gene cassette was 
inserted in between the NPTII and GUS genes as illustrated in Figure 3- 21). 
Figure 4- 6 GUS staining of transgenic and wild type tobacco leaves 
Fresh tobacco leaves were placed in GUS staining solution for color 
development. Chlorophyll was removed by 70% ethanol. Leaves 
、from transgenic tobacco was stained deep blue (left 3 tubes) while the 
wild type sample (right) was colorless. 
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4.5 Detection of transgene integration 
In spite of using indirect means such as antibiotic selection and GUS assay, it is 
necessary to confirm the integration of target gene (IGF-I or IGFBP-3) into the 
tobacco genome by molecular approaches, such as PCR and Southern blot. 
4.5.1 Extraction of genomic DNA and PCR 
Genomic DNA was isolated from transgenic tobacco leaves using the CTAB 
method (Figure 4- 7). PCR was performed using IGF-I or IGFBP-3 specific 
primers, 35IGFL and 35IGFR or 35BP-3L and 35BP-3R (Figure 3- 13)，and genomic 
DNA as the template. The 210 bp PCR product for IGF-I (Figure 4- 8) and 800bp 
PCR product for IGFBP-3 (Figure 4- 9) were obtained. Genomic DNA of the wild 
type (WT) plant and the negative control (no template was added in the PCR reaction) 
did not amplify the band. Positive control, using pBI/Phas/IGF-I or 
pBI/Phas/IGFBP-3 as the template, was also carried out. The results indicated that 
the transgene was present in the genome of the transgenic plants. 
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Figure 4- 7 Genomic DNA extracted from tobacco leaves and resolved in 
0.8% agarose gel 
Lanes 1-3: pBI/35S/IGF-I transformants 311,2 and 5; 
Lanes 4-6: pBI/Phas/IGF-I transformants PI1,2 and 4; 
Lanes 7-9: pBI/Phas/SP::IGF-I transformants SIl, 4 and 5; 
Lanes 10-12: pBI/Phas/SP::IGF-I::AFVY transformants 
SIA2, 5 and 8; 
、 Lanes 13-15: pBI/Phas/LRP 1 ::IGF-I::LRP2 transformants 
IFul,2and3; 
Lanes 16-17: pBI/35S/IGF-I::GUS transformants IGFu2 and 3; 
Lanes 18-20: pBI/Phas/IGFBP-3 transformants PBl, 3 and 6; 
. Lanes 21-24: pBI/Phas/SP::IGFBP-3 transformants SBl, 2，4 and 9; 
Lanes 25-28: pBI/Phas/SP::IGFBP-3::AFVY transformants 
SBAl,2,3and4; 
Lanes 29-32: pBI/Phas/LRPl::IGFBP-3::LRP2 transformants 
BFul, 4，5 and 6; 
Lanes 33-36: pBI/35S/IGFBP-3::GUS transformants BGFu. 
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Figure 4- 8 PCR analysis of genomic DNA of IGF-I transformants 
PGR, using genomic DNA from the wild type (WT) tobacco plant or 
the IGF-I transformants as the template, was performed with the IGF-I 
specific primers 35IGFL and 35IGFR. PCR using plasmid 
pBI/Phas/IGF-I as the template was the positive (+ve) control. The 
expected size of PCR product was 210 bp. The negative control, 
using ddH20 as the template, was also performed. 
Lane 1: pBI/35S/IGF-I transformant 311; 
Lane 2: pBI/Phas/IGF-I transformant PIl ； 
Lane 3: pBI/Phas/SP::IGF-I transformant SIl; 
Lane 4: pBI/Phas/SP::IGF-I::AFVY transformant SIA2; 
Lane 5: pBI/Phas/LRPl::IGF-I::LRP2 transformant IFul; 
Lane 6: pBI/35S/IGF-I::GUS transformant IGFu2; 
Lane 7: Wild type (WT) tobacco; 
Lane 8: pBI/Phas/LRPl::IGFBP-3::LRP2 transformants BFul; 
Lane 9: pBI/35S/IGFBP-3::GUS transformants BGFul; 
Lane 10: +ve control (pBI/Phas/IGF-I); 
Lane 11: -ve control (ddHzO); 
Lane 12: 100 bp DNA ladder (Invitrogen). 
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Figure 4- 9 PCR analysis of genomic DNA of IGFBP-3 transformants 
PCR, using genomic DNA from the wild type (WT) tobacco plant or 
IGFBP-3 transformants as the template, was performed with the 
IGFBP-3 specific primers 35BP-3L and 35BP-3R. PCR using 
plasmid pBI/Phas/IGFBP-3 as the template was used as positive (+ve) 
control. The expected size of PCR product was 800 bp. The 
negative control, using ddHzO as the template, was also performed. 
Lane 1: Ikb DNA ladder (Invitrogen); 
Lanes 2-3: pBI/Phas/IGFBP-3 transformants PBI and 3; 
Lanes 4-5: pBI/Phas/SP::IGFBP-3 transformants SBl and 2; 
Lanes 6-8: pBI/Phas/SP::IGFBP-3::AFVY transformants 
SBAl,2and3; 
Lanes 9-15: pBI/Phas/LRP 1::IGFBP-3::LRP2 transformants 
BFul,4,5,6, 7, 8 and 9; 
Lanes 16-18: pBI/35S/IGFBP-3::GUS transformants 
* 
BGFul,3and 6; 
Lane 19: Wild type (WT) tobacco; 
Lane 20: pBI/Phas/LRP 1::IGF-I::LRP2 transformants IFul ； 
Lane 21: +ve control (pBI/Phas/IGFBP-3); 
Lane 22: -ve control (ddHzO). 
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4.5.2 Southern blot analysis 
Southern blot analysis was performed to confirm the transgene integration. 
Genomic DNA was digested with restriction enzyme (Hindlll or BamHI), separated 
by gel electrophoresis and blotted on nylon membrane. After hybridization with 
一 DIG-labeled DNA probe, chemiluminescent detection was carried out. As the 
enzyme cuts only once on the pBI 121 vector but not the transgene, the copy number 
of the transgene integration could be estimated. Most of the transformants contain 
1 to 2 copies of the transgenes. 
The genomic DNA from the IGFu and BGFu transformants (with 
pBI/35S/IGF-I or IGFBP-3::GUS) were digested with Hindlll (Figure 4- 10) while 
that from other transformants were with BamHI (Figures 4- 11 and 4- 12). No 
signal was detected in the wild type plant. These results confirmed the presence 
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Figure 4-10 Southern blot analysis of genomic DNA from transformants 
IGFu and BGFu 
Genomic DNA extracted from the tobacco leaves was digested with 
Hindlll, separated on 0.8% agarose gel (upper panels), blotted on the 
positively charged nylon membrane and hybridized with DIG-labeled 
IGF-I probe (lower left panel) or IGFBP-3 probe (lower right panel). 
Lanes 1-4: pBI/35S/IGF-I::GUS transformants IGFu2, 3,4 and 6; 
‘ Lanes 5-7: pBI/35S/IGFBP-3::GUS transformants 
、 BGFu3, 6 and 7. 
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Figure 4-11 Southern blot analysis of genomic DNA from transformants 
31，PI, SI, SIA and IFu 
Genomic DNA extracted from the tobacco leaves was digested with 
BamHI, separated on 0.8% agarose gel (upper panel), blotted on the 
positively charged nylon membrane and hybridized with DIG-labeled 
IGF-I probe (lower panel). 
Lane 1: DNA molecular weight VII，DIG-labeled (Roche); 
• Lane 2: pBI/35S/IGF-I transformant 311 ； 
Lane 3: pBI/Phas/IGF-I transformant PIl ； 
Lane 4: pBI/Phas/SP::IGF-I transformant SIl; 
Lane 5: pBI/Phas/SP::IGF-I::AFVY transformant SIA2; 
Lanes 6-7: pBI/Phas/LRP 1::IGF-I::LRP2 transformants 
IFul and 2; 
Lane 8: Wild type (WT) tobacco. 
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Figure 4-12 Southern blot analysis of genomic DNA from transformants 
PB, SB, SBA and BFu 
、 Genomic DNA extracted from the tobacco leaves was digested with 
BamHI, separated on 0.8% agarose gel (upper panel), blotted on the 
positively charged nylon membrane and hybridized with DIG-labeled 
IGFBP-3 probe (lower panel). 
• • 
, Lane 1: pBI/Phas/IGFBP-3 transformant PB 1 ； 
Lane 2: “ pBI/Phas/SP::IGFBP-3 transformant SBl; 
Lanes 3-4: pBI/Phas/SP::IGFBP-3::AFVY transformants 
SBAl and 2; 
Lanes 5-6: pBI/Phas/LRPl ::IGFBP-3::LRP2 transformants 
BFul and 4. 
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4.6 Detection of transgene transcription 
Northern blot analysis was performed to study the presence and transcriptional 
level of expression of transgene in the transformants. 
4.6.1 Extraction of total RNA 
Total RNA was extracted from the developing seeds (collected 18 to 20 DAF) of 
the transformants harboring the seed-specific phaseolin promoter constructs 
(pBI/Phas/IGF-I or IGFBP-3, pBI/Phas/SP::IGF-I or IGFBP-3, pBI/Phas/SP::IGF-I 
or IGFBP-3::AFVY and pBI/Phas/LRPl::IGF-I or IGFBP-3::LRP2) (Figure 4- 13). 
Total RNA was extracted from the leaves of the transformants harboring the 
constitutive CaMV 35S promoter constructs (pBI/35S/IGF-I and pBI/35S/IGF-I or 
IGFBP-3 ::GUS) (Figure 4-14). 
4.6.2 Northern blot analysis 
Total RNA was separated by gel electrophoresis, blotted on nylon membrane 
and hybridized with DIG-labeled probe. Hybridization and chemiluminescent 
‘detection were carried out similar to that in the Southern blot analysis. 
I 
As revealed in Figures 4- 15 and 4- 16，eight different transformants, 
pBI/Phas/IGFBP-3 (PB), pBI/Phas/LRPl::IGF-I::LRP2 (IFu), 
pBLThas/LRP 1: :IGFBP-3: :LRP2 (BFu), pBI/35S/IGF-I::GUS (IGFu), 
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pBI/35S/IGFBP-3::GUS (BGFu), pBI/Phas/SP::IGF-I (SI), pBI/Phas/SP::IGFBP-3 
(SB) and pBI/Phas/SP::IGFBP-3::AFVY (SBA) showed positive signals in the 
northern blot analysis. No signal was detected in the transformants pBI/Phas/IGF-I 
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Figure 4- 13 Total RNA from tobacco developing seeds 
Total RNA extracted from tobacco developing seeds was separated on 
0.8% agarose/formaldehyde gel. 
Lane 1: 0.24-9.5Kb RNA ladder (Invitrogen); 
Lanes 2-4: pBI/Phas/IGF-I transformants PIl，2 and 4; 
Lanes 5-7: pBI/Phas/IGFBP-3 transformants PBl, 3 and 6; 
Lanes 8-9: pBI/Phas/LRPI ::IGF-I::LRP2 transformants 
IFul and 2; 
Lanes 10-11: pBI/Phas/LRP 1 ::IGFBP-3::LRP2 transformants 
BFul and 4; 
Lanes 12-14: pBI/Phas/SP::IGF-I::AFVY transformants 
SIA2 5 and 8; 
Lanes 15-17: pBI/Phas/SP::IGF-I transformants SIl, 4 and 5; 
t 
、Lanes 18-20: pBI/Phas/SP::IGFBP-3:: AFVY transformants 
SBAl,2and3; 
Lanes 21-22: pBI/Phas/SP::IGFBP-3 transformants SBl and 2. 
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Figure 4-14 Total RNA from tobacco leaves 
Total RNA extracted from tobacco leaves was separated on 0.8% 
agarose/formaldehyde gel. 
Lanes 1-3: pBI/35S/IGF-I transformants 311，2 and 5; 
Lanes 4-6: pBI/35S/IGF-I::GUS transformants IGFu2, 3 and 4; 
Lanes 7-10: pBI/35S/IGFBP-3::GUS transformants 
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Figure 4- 15 Northern blot analysis of total RNA from transformants 
31，IGFu and BGFu 
Total RNA extracted from tobacco leaves was separated on 0.8% 
agarose/formaldehyde gel, blotted onto the positively charged nylon 
membrane and hybridized with the DIG-labeled IGF-I (upper panel) 
or IGFBP-3 (lower panel) probe. 
Lanes 1 & 8: Wild type (WT) tobacco; 
Lanes 2-4: pBI/35S/IGF-I::GUS transformants IGFu2, 3 and 4; 
Lanes 5-7: pBI/35S/IGF-I transformants 311，2 and 5; 
Lanes 9-12: pBI/35S/IGFBP-3::GUS transformants 
BGFu3, 6, 7 and 8; 
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Figure 4-16 Northern blot analysis of total RNA from transformants 
PI, IFu, SIA and SI 
Total RNA extracted from tobacco developing seeds was separated on 
0.8% agarose/formaldehyde gel, blotted onto the positively charged 
nylon membrane and hybridized with the DIG-labeled IGF-I probe. 
Lanes 1-3: pBI/Phas/IGF-I transformants PIl, 2 and 4; 
Lanes 4-6: pBI/Phas/LRPl ::IGF-I::LRP2 transformants 
IFul, 2 and 3; 
Lane 7: Wild type (WT) tobacco; 
Lanes 8-10: pBI/Phas/SP::IGF-I::AFVY transformants 
SIA2, 5 and 8; 
、Lanes 11-14: pBI/Phas/SP::IGF-I transformants 
SIl ,4,5and 6. 
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Figure 4-17 Northern blot analysis of total RNA from transformants 
PB, BFu, SB and SBA 
Total RNA extracted from tobacco developing seeds was separated on 
0.8% agarose/formaldehyde gel, blotted onto the positively charged 
nylon membrane and hybridized with the DIG-labeled IGFBP-3 
probe. 
Lanes 1-2: pBI/Phas/IGFBP-3 transformants PBI and 3; 
Lane 3: 0.24-9.5Kb RNA ladder (Invitrogen); 
Lane 4: Wild type (WT) tobacco; 
Lanes 5-8: pBI/Phas/LRP 1::IGFBP-3::LRP2 transformants 
BFul ,4 ,5andl l ; 
Lanes 9-11: pBI/Phas/SP::IGFBP-3 transformants 
SBl,2and 4; 




4.7 Detection of transgene translation 
4.7.1 Extraction of total protein and Tricine SDS-PAGE 
Total protein was extracted with Tris extraction buffer from mature seeds of 
phaseolin promoter transformants (PB, IFu, BFu, SI, SBA and SB) or from leaves of 
CaMV 35S promoter transformants (IGFu and BGFu). The protein profiles were 
revealed by 17% Tricine SDS-PAGE after staining with Coomassie blue solution 
(Figures 4- 18 and 4- 19). The putative recombinant IGF-I and IGFBP-3 proteins of 
CaMV35S or phaseolin promoter only constructs and the phaseolin targeting 
constructs should have molecular weights (MW) of about 7.5 and 45 kDa 
respectively. The estimated MW of recombinant IGF-I and IGFBP-3 proteins with 
GUS fusion should be about 70 and 86 kDa respectively while that with LRP fusion 
is about 26 and 51 kDa respectively. However, no obvious difference could be 
observed between the protein profiles of the wild type plant and the transformants. 
The amount of recombinant proteins might not be sufficiently abundant to be 
detected with Coomassie blue staining. 
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Figure 4-18 Tricine SDS-PAGE of total protein from tobacco mature seeds 
Total protein (40 ug) was obtained from tobacco mature seeds, 
resolved in 17% Tricine SDS-PAGE and stained with Coomassie blue. 
Lane 1: BenchMark Protein Ladder (Invitrogen); 
Lane 2: Wild type (WT) tobacco; 
Lanes 3-4: pBI/Phas/LRPl ::IGF-I::LRP2 transformants 
IFul and 3; 
Lane 5: pBI/Phas/SP::IGF-I transformant SIl； 
Lane 6: pBI/Phas/IGFBP-3 transformant PBI; 
Lane 7: pBI/Phas/LRPI ::IGFBP-3::LRP2 transformant BFul; 
Lane 8: pBI/Phas/SP::IGFBP-3 transformant SBl; 
Lane 9: pBI/Phas/SP::IGFBP-3::AFVY transformant SBAl. 
t 
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Figure 4- 19 Tricine SDS-PAGE of total protein from tobacco leaves 
Total protein (100 ug) was obtained from tobacco leaves, resolved in 
17% Tricine SDS-PAGE and stained with Coomassie blue. 
Lanes 1-4: pBI/35S/IGFBP-3::GUS transformants 
BGFu3, 6，7 and 8; 
Lane 5: Wild type (WT) tobacco; 
Lane 6: BenchMark Protein Ladder (Invitrogen); 




4.7.2 Western blot analysis 
Western blot analysis was performed, as it was more sensitive and precise for 
protein detection. Protein extract was separated on 17% Tricine SDS-PAGE and 
blotted onto PVDF membrane (Bio-Rad). Anti-human IGF-I or IGFBP-3 
polyclonal antibody (Santa Cruz) at 1:200 dilution was used for immunodetection. 
Recombinant human IGF-I and IGFBP-3 proteins produced from E. coli (Gropep) 
were used as the positive controls, their MW were about 7.5 kDa and 45 kDa 
respectively. After chemiluminescent detection, the transformants harboring the 
targeting constructs, with or without AFVY, of IGFBP-3 (SBAl, 2 and 3; SB 1, 4 and 
9) and LRP fusion constructs of both IGF-I and IGFBP-3 (IFul and 3; BFul, 4，5 and 
11) showed positive signals. However, no expression could be detected in other 
transformants (Figures 4- 20 to 4- 23). 
The expression level of recombinant IGFBP-3 of pBI/Phas/SP::IGFBP-3 (SB) 
and pBI/Phas/SP: :IGFBP-3::AFVY (SBA) transformants was also compared. Total 
protein was extracted with 100 ul SDS-Tris buffer from 20 mg tobacco mature seeds 
of the transformants SBAl and SBl. Different amounts of total protein were 
resolved in 17% Tricine SDS-PAGE and blotted on PVDF membrane. Western blot 
analysis using Anti-human IGFBP-3 polyclonal antibody was carried out. 
Recombinant human IGFBP-3 protein was used as the standard to estimate of the 
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amount of recombinant IGFBP-3 in these transformants. As shown in Figure 4- 24， 
the expression level of recombinant IGFBP-3 was much higher in transformant 
SBAl than that in SBl. To estimate the IGFBP-3 expression level in transformant 
SBAl, 0.02 g of tobacco seed with 100 ul of extraction buffer was used. From the 
100 ul of extracted protein, 10 ul (equivalent to protein extracted from 2 mg seed) 
was loaded into a protein gel to compare with a series of known concentrations of 
commercial rhIGFBP-3. Through western blotting analysis, the extracted protein 
was estimated to contain 0.8 ug of the commercial protein. As the amount of 
protein loaded into the gel was equivalent to the protein extracted from 2 mg of seed, 
it was estimated that about 400 ug of recombinant human IGFBP-3 could be obtained 
from 1 g of transgenic tobacco seeds, representing 0.04% of the total seed weight. 
As total seed protein accounts for 10% of the seed weight, rhIGFBP-3 thus amounts 
to about 0.4% of the total seed protein. 
* 
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Figure 4- 20 Western blot analysis of leaf total protein from transformants 
IGFu and BGFu 
Total protein (150 ug) was extracted from tobacco leaves, resolved in 
17% Tricine SDS-PAGE and blotted on PVDF membrane. Western 
blot analysis using Anti-human IGF-I (upper panel) or IGFBP-3 
(lower panel) polyclonal antibody (Santa Cruz) was carried out. 
Recombinant human IGF-I or IGFBP-3 protein (125 ng; Gropep) was 
used as the positive control. 
Lane 1: Blank; 
Lanes 2-4: pBI/35S/IGF-I::GUS transformants 
IGFu2, 3 and 4; 
‘ . Lanes 5 & 12: Wild type (WT) tobacco; 
Lanes 6 & 13 : Precision Plus Protein Dual Color Standards; 
Lane 7: Recombinant human IGF-I protein; 
Lanes 8-11: pBI/35S/IGFBP-3::GUS transformants 
BGFu3, 6，7 and 8; 
Lane 14: Recombinant human IGFBP-3 protein. 
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Figure 4- 21 Western blot analysis of seed total protein from transformants 
IFu and SI 
Total protein (50 ug) was extracted from tobacco seeds, resolved in 
17% Tricine SDS-PAGE and blotted on PVDF membrane. Western 
blot analysis using Anti-human IGF-I polyclonal antibody (Santa Cruz) 
was carried out. 
Lanes 1-2: pBI/Phas/LRPI ::IGF-I::LRP2 transformants 
EFul and 3; 
Lane 3: Wild type (WT) tobacco; 
Lanes 4-6: pBI/Phas/SP::IGF-I transformants SIl, 4 and 5. 
» 
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Figure 4- 22 Western blot analysis of seed total protein from transformants 
BFu and PB 
Total protein (50 ug) was extracted from tobacco seeds, resolved in 
17% Tricine SDS-PAGE and blotted on PVDF membrane. Western 
blot analysis using Anti-human IGFBP-3 polyclonal antibody (Santa 
Cruz) was carried out. 
Lanes 1-4: pBI/Phas/LRPI ::IGFBP-3::LRP2 transformants 
BFul ,4 ,5andl l ; 
Lane 5: Wild type (WT) tobacco; 
Lanes 6-7: pBI/Phas/IGFBP-3 transformants PBI and 3. 
> 
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Figure 4- 23 Western blot analysis of seed total protein from transformants 
SB and SBA 
Total protein (50 ug) was extracted from tobacco seeds, resolved in 
17% Tricine SDS-PAGE and blotted on PVDF membrane. Western 
blot analysis using Anti-human IGFBP-3 polyclonal antibody (Santa 
Cruz) was carried out. Recombinant human IGFBP-3 protein (125 
ng; Gropep) was used as the positive control. 
Lanes 1 & 6: Recombinant human IGFBP-3 protein; 
Lanes 2-4: pBI/Phas/SP::IGFBP-3 transformants SBl, 4 and 9; 
Lane 5: Wild type (WT) tobacco; 
Lanes 7-9: pBI/Phas/SP::IGFBP-3::AFVY transformants 
SBAl, 2 and 3; 
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Figure 4- 24 Western blot analysis to compare the expression level of 
recombinant IGFBP-3 in transformants SBAl and SBl 
in tobacco seeds 
Total protein was extracted with 100 ul SDS-Tris buffer from 20 mg 
tobacco mature seeds of the transformants SBAl and SBl. Different 
amounts of total protein were resolved in 17% Tricine SDS-PAGE and 
blotted on PVDF membrane. Western blot analysis using 
Anti-human IGFBP-3 polyclonal antibody (Santa Cruz) was carried 
out. Recombinant human IGFBP-3 protein (Gropep) was used as the 
standard to estimate of the amount of recombinant IGFBP-3 in these 
transformants. 
Lanes 1-3: pBI/Phas/SP::IGFBP-3::AFVY transformants SBAl 
2 ul, lOul and 15 ul; 
Lanes 4-6: pBI/Phas/SP::IGFBP-3 transformants SBl 
2ul,10ul and 15 ul; 
Lane 7: Precision Plus Protein Dual Color Standards; 
“ Lanes 8-10: Recombinant human IGFBP-3 protein 
0.1 ug, 0.5 ug and 1 ug. 
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4.7.3 Enterokinase digestion of fusion protein 
Two enterokinase (EK) sites were incorporated into the LRP fusion proteins 
(section 3.2.6.2.2) in order to release the IGF-I or IGFBP-3 via the EK digestion for 
further purification. 
Both LRP/IGF-I and LRP/IGFBP-3 fusion proteins could be detected in 
transgenic tobacco by western blot as described in section 4.7.2. Theoretically, 
three protein fragments, LRPl-EK (5.5 kDa), IGFBP-3-EK (33 kDa) and LRP2 (12.5 
kDa), could be obtained after the EK digestion. 
Total seed protein (150 ug) from the transformant BFul was digested with EK 
at 20°C for 2, 4 and 6 hours. A control was also carried out with no EK added to 
the digestion. The samples were resolved in 17% Tricine SDS-PAGE and blotted 
on PVDF membrane for immunodetection with anti-LRP or anti-human IGFBP-3 
antibody (Figure 4- 25). However, no such three fragments could be detected. 
The LRP/IGFBP-3 protein disappeared after 2 hours of the EK digestion (with or 
without EK added). The recombinant protein might be unstable itself or be 
degraded by other unknown protein(s) in the extraction buffer or reaction mixture 
during prolonged EK digestion. 
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Figure 4- 25 Western blot analysis for the EK digestion of transformant BFul 
Total seed protein (150 ug) from transformant BFul was digested 
with EK at 20°C for 2, 4 and 6 hours, resolved in 17% Tricine 
SDS-PAGE and blotted on PVDF membrane for immunodetection 
with anti-LRP (upper panel) or anti-human IGFBP-3 (lower panel) 
‘ ‘ 
. antibody. A control was also carried out with no EK added to the 
digestion. 
Lanes 1-4: pBI/Phas/LRP 1::IGFBP-3::LRP2 transformant BFul 
with EK digestion at 0，2，4 and 6 hr; 
Lanes 5-7: pBI/Phas/LRP 1::IGFBP-3::LRP2 transformant BFul 
with EK digestion (no EK added) at 2，4 and 6 hr; 
Lane 8: Precision Plus Protein Dual Color Standards. 
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Chapter 5 Discussion 
Diabetes mellitus is a common disorder and affects about 10% of Hong Kong 
Chinese. Abnormal regulation of growth hormone (GH) / insulin-like growth 
factor-I (IGF-I) axis is well documented in patients with diabetes, particularly among 
those who are insulin deficient. Treatment with recombinant human IGF-I (rhlGF-I) 
has been shown to improve glycaemic control and the requirement of insulin doses. 
The addition of recombinant human IGF binding protein-3 (rhIGFBP-3) to rhlGF-I 
alleviates the adverse effects that are commonly associated with high dose rhIGF-I 
therapy. The limiting step in the development of rhIGF-I and rhIGFBP-3 as 
therapeutic option is the availability of recombinant proteins at low cost. 
Successful expression of IGF-I production in E. coli (Chung et al.’ 2000), sarcoma 
cell lines (Bernstein et al.’ 2001) and transgenic mice (Su et al., 1999) have been 
reported. However, so far, there has been no publication on IGF-I or IGFBP-3 
expression in plants. 
' Among the different heterologous protein production systems available today, 
> 
plants are particularly attractive as large-scale production systems for proteins 
because they can be grown easily and inexpensively in large quantities with the 
available agronomic infrastructures. Moreover, plant systems can produce correctly 
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folded eukaryotic proteins and perform most of the post-translational modifications 
required. Furthermore, safe recombinant proteins can be obtained, as contamination 
of expressed proteins with human or animal pathogens or other infectious diseases 
will not occur in plants (Fischer and Emans, 2000). Despite all the above 
advantages, introducing a foreign gene into a plant host does not always result in 
high-level expression or even expression of the introduced gene at all. Effective use 
of plants as bioreactors thus depends on the ability to obtain high protein 
accumulation levels that are stable during the life cycle of a transgenic plant and in 
subsequent generations. 
In this study, codon modified human IGF-I and IGFBP-3 cDNAs in different 
expression vectors were introduced into tobacco via Agrobacterium-mQ^idXQd. 
transformation. Regenerated plants were first selected based on their kanamycin 
resistance (NPTII gene expression) and then screened with GUS assay (GUS gene 
expression). In genomic DNA PCR (Figures 4- 8 and 4- 9) and Southern blot 
analysis (Figures 4- 10 to 4- 12)，the transgenic plants showed positive results 
‘confirming the transgene integration into tobacco genome. The presences of the 
> 
transgene transcripts in some of the transformants including the pBI/Phas/IGFBP-3 
(PB), pBI/Phas/LRPI::IGF-I::LRP2 (IFu), pBI/Phas/LRP 1::IGFBP-3::LRP2 (BFu), 
pBI/35S/IGF-I::GUS (IGFu), pBI/35S/IGFBP-3::GUS (BGFu), pBI/Phas/SP::IGF-I 
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(SI), pBI/Phas/SP::IGFBP-3 (SB) and pBI/Phas/SP::IGFBP-3::AFVY (SBA) were 
revealed by northern blot analysis (Figures 4- 15 to 4- 17). However, only the 
transformants harboring the LRP fusion constructs of both IGF-I and IGFBP-3 (EFul 
and 3; BFul, 4, 5 and 11) and the targeting constructs, with or without AFVY, of 
IGFBP-3 (SBAl, 2 and 3; SBl, 4 and 9) showed positive signals in western blot 
analysis. Successful expression of the transgenes may be due to the codon 
modification and the stabilizing effect of LRP or subcellular targeting. No 
expression could be detected in other transformants (Figures 4- 20 to 4- 23). Gene 




5.1 Codon modification of IGF-I and IGFBP-3 cDNAs 
In this study, human IGF-I and IGFBP-3 cDNAs were first codon modified to 
enhance their expression in plants. 
With the exception of Met and Tip, all amino acids are encoded by two to six 
synonymous codons. Nonrandom usage of synonymous codons is a widespread 
phenomenon in the majority of species studied to date. This codon bias is 
suggested to be related to the abundance of corresponding isoaccepting tRNA so as 
to ensure translation accuracy and efficiency (Ikemura, 1982). The choice of 
codons has been thought to affect the translation rate. A probable mechanism in 
explaining the negative influence of the rare codons on translation is that a ribosome 
may stall when encountering a rare codon as it may take longer time for a rare tRNA 
to enter the A-site of the ribosome (Yanofsky, 1981). 
One example on enhanced gene expression in plants by changing the rare 
codons to more typical ones is the green fluorescent protein (GFP) from Aequorea 
victoria. By increasing the G+C content of the gene and removing the cryptic 
» 
introns and potential polyadenylation sites, one full-size GFP was found in transgenic 
tobacco while only small and truncated fragments of wild-type GFP were observed in 
transgenic plants harboring the unmodified gene (Rouwendal et al.，1997). 
Based on the assumption that the more frequently used codons have a greater 
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proportion of tRNAs and hence better translation, these frequently used codons are 
thus more preferred in that organism. As IGF-I and IGFBP-3 cDNAs are originated 
from human; their differences in codon usage from plants might result in poor 
expression. The codons of the IGF-I and IGFBP-3 cDNAs were modified based on 
the preferred codons used in two seed storage proteins. Codon usage of lysine-rich 
protein (LRP) from winged bean and methionine-rich 2S albumin (PN2S) from 
Paradise nut were chosen as the bases for modification because high expression and 
stable accumulation (3-10% and 3-15% of total extractable seed proteins for LRP and 
PN2S, respectively) in transgenic Arabidopsis was observed in previous studies 
(Cheng, 1999; Chen, 2000). The change of codon of IGF-I and IGFBP-3 were 
28.6% and 14.8% respectively. 
I 
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5.2 Transient expression of IGF-I and IGFBP-3 cDNAs 
The problems of codon usage exist in different species. As the target genes to 
be transformed are usually not originated from plant, whether the target genes are 
translatable in the desired plant has always posed a problem in developing the 
expression system. 
In the present study, the in vivo translatability of the IGF-I and IGFBP-3 cDNAs 
was investigated by transient expression of the transgenes in soybean cotyledons and 
tobacco leaves. The codon modified IGF-I or IGFBP-3 cDNA was fused with the 
GUS gene which has its first ATG start codon removed. These chimeric fusion 
genes were put under the control of the CaMV 35S promoter in the pBI221 
expression vector, which were then introduced into the plant cells by particle 
bombardment. The translatability of the transgene was revealed by the GUS 
reporter gene: if the transgene could be translated, a GUS fusion protein would be 
produced and active sites in the GUS protein moiety would turn the substrate X-Glu 
in the GUS staining solution blue. Blue spots would be observed in the plant 
, t issues. If the transgene could not be translated, no spot would be found on the 
> 
plant tissues. 
After particle bombardment and GUS assay, constructs pBI221 (positive 
control), pBI221/35S/IGF-I::GUS and pBI221/35S/IGFBP-3::GUS showed blue 
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spots on both soybean cotyledons and tobacco leaves (Figure 4- 2). The results 
indicate that the IGF-I and IGFBP-3 cDNAs are transcribed and translated in plants. 
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5.3 Fusion of IGF-I and IGFBP-S cDNAs with LRP gene 
As mentioned in the earlier sections, the transformants harboring the LRP fusion 
construct (both for IGF-I and IGFBP-3) demonstrated transgene expression at protein 
level. 
Since LRP has been expressed at relatively high levels (3-10% of the total 
extractable protein) in transgenic Arabidopsis (Cheng, 1999X it must be readily 
translated and remain stable inside the plant cells. The LRP gene itself may contain 
some protein-stabilizing signals/structure that would be useful in enhancing the 
transgene expression in plants. In this study, the IGF-I or IGFBP-3 cDNA was 
inserted into the random-coil region of the LRP, so as to minimize the interference to 
the original LRP confirmation. 
From the western blot results, IFu (pBI/Phas/LRPI ::IGF-I::LRP2) and BFu 
(pBI/Phas/LRPI ::IGFBP-3::LRP2) had recombinant protein expression as signals of 
the expected sizes were detected (Figures 4- 21 and 22). The LRP fusion might 
have stabilizing effect to the transgene on translational and/or post-translational level. 
* 
It might enhance transgene translation, protect the recombinant proteins and allow 
the recombinant proteins to accumulate. Importantly, IFu is the only IGF-I 
c 
constructs that could be expressed in transgenic tobacco. As IGF-I is small in size 
(only 7.5 kDa), fusion of it with LRP increased its size and might make it more stable 
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in the cell. 
LRP is a cytosolic protein and its gene does not have signaling sequence for 
LRP to enter endoplasmic reticulum (ER) and Golgi. No glycosylation was found 
in the EFu and BFu recombinant proteins as indicated from their molecular weights. 
This result supports the notion that no signaling sequence was provided in the 
chimeric constructs. The recombinant proteins, similar to LRP, would not enter ER 
and Golgi, so no glycosylation would be added to the recombinant proteins. IGF-I 
processes only one 0-glycosylation site, so the absence of glycosylation in rhIGF-I 
may not affect its functions. In contract, IGFBP-3 has three N-glycosylation sites 
that might modulate the cell-binding activity. However, the carbohydrate units 
appear to be non-essential to ALS or IGF binding (Firth and Baxter, 1999). Hence, 
the biological activity of the non-glycosylated recombinant proteins may not be 
affected. Further studies are required to examine the function of these recombinant 




5.4 Enterokinase digestion 
To further purify the recombinant proteins for biological activity assays, 
enterokinase (EK) digestion was performed with the total protein extract of the LRP 
fusion transformants. 
EK is a trypsin-like serine protease which plays a key role in converting 
trypsinogen to trypsin via a highly specific cleavage following the pentapeptide 
recognition sequence (Asp-Asp-Asp-Asp-Lys). This stringent site specificity 
enables EK to serve as a fusion protein cleavage reagent. In 1995, Collins-Racie et 
al. demonstrated the use and production of recombinant EK in E. coli. The EK 
cDNA was fused to the 3’ end of a secreted thioredoxin homolog, DsbA, with a 
linker sequence encoding the EK recognition site in between. Active, processed 
recombinant EK was generated from the fusion protein via autocatalytic cleavage. 
In this study, two EK recognition sites were introduced (flanking the IGF-I and 
IGFBP-3 cDNAs) in the LRP fusion constructs which could be used to separate the 
target proteins from LRP. After EK digestion, the LRP/IGFBP-3 fusion protein 
» 
from transformant BFul disappeared. The recombinant protein might be unstable 
and degraded by other enzymes, such as proteases in the extraction buffer or reaction 
mixture during prolonged EK digestion. In future study, pure fusion proteins 
should be extracted from the crude protein sample by affinity chromatography before 
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carrying out the EK digestion. 
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5.5 Phaseolin targeting signal 
Besides the transformants with LRP fusion constructs, the transformants 
harboring the phaseolin targeting constructs, with or without AFVY, of IGFBP-3 also 
had recombinant protein expression. 
According to Frigerio et al. (1998)，removal of the last four C-terminal amino 
acids, AFVY (Ala, Phe, Val and Tyr) allows correct trimer formation but causes 
phaseolin to be secreted into apoplast instead of accumulated in the protein storage 
vacuole (PSV). The fact that the AFVY tetrapeptide alone is sufficient for sorting 
protein to the vacuole was further demonstrated by fusing this tetrapeptide to a 
secreted version of GFP under the control of CaMV 35S promoter. After 
transfecting the fusion construct into tobacco protoplasts, the reporter GFP was 
redirected to and accumulated in vacuoles (Frigerio et al” 2001). 
In the present study, two kinds of phaseolin targeting constructs (with phaseolin 
promoter and signal peptide) were made. The constructs with the C-terminal AFVY 
(SIA and SBA) would target the recombinant proteins to PSV while those without 
» 
(SI and SB) might be secreted to apoplast. No recombinant IGF-I was detected in 
transformants SI. This might be due to the small size and instability of IGF-I 
protein. On the other hand, rhIGFBP-3 could be detected in both transformants SB 
and SBA. However, when comparing the expression level of rhIGFBP-3, 
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transformant SB A was much higher than that of SB. These results suggested that 
PSV could provide a more suitable and stable environment for protein accumulation 
than apoplast. As mentioned in section 4.7.2，the rhIGFBP-3 expression in SBAl 
could be up to 0.4% of the total seed proteins. It is feasible to produce rhIGFBP-3 




5.6 Gene silencing 
Table 5- 1 Summary of results on transgene constructs integration, 
transcription and translation 
Construction Number of Transgene Transcription Translation 
(in pBI 121) transgenic integration  
plant  
35S/IGF-I (31) 40 + - -
Phas/IGF-I (PI) 17 + - -
Phas/SP::IGF-I (SI) 6 + + -
Phas/SP::IGF-I::AFVY (SIA) 37 + - -
Phas/LRP1::IGF-I::LRP2 (IFu) 10 + + + 
35S/IGF-I ::GUS (IGFu) 7 + + -
Phas/IGFBP-3 (PB) II + + -
Phas/SP::IGFBP-3 (SB) 6 + + + 
Phas/SP::IGFBP.3::AFV (SBA) 7 + + + 
Phas/LRP1::IGFBP-3::LRP2 (BFu) 10 + + + 
35S/IGFBP-3 ::GUS (BGFu) 6 + + -
As indicated in the transient assay, the codon modified IGF-I and IGFBP-3 
cDNAs could be transcribed and translated in plants. However, transcripts or 
proteins of transgenes were not detected in all the transformants. As summarized in 
table 5- 1，constructs with IGF-I yielded no protein except the LRP fusion construct. 
> 
Other IGF-I constructs are expected to yield a mRNA with a molecular weight below 
400bp, perhaps because of their small size or primary structure, unstable mRNA or 
protein was resulted. Compared with the IGFBP-3 constructs, PI and SIA did not 
produce detectable mRNA while the larger IGFBP-3 equivalent (PB, SBA) does, 
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suggesting the larger size mRNA and protein might be more stable. 
LRP fusion with IGF-I and IGFBP-3 resulted in successful transcription and 
translation, further suggesting the fusion structure and/or increased size can stabilize 
the mRNA and protein molecules. However, IGFu and BGFu fusion constructs did 
not yield detectable protein. Since they are controlled by 35S promoter, which is a 
weak promoter in comparison to phaseolin, the trace amounts of protein expressed 
might not be detectable or the protein was degraded in the plant tissues. This might 
also have occurred in the 31 construct. 
IGF-I is a hormone with a relatively short life. The half life of free IGF-I in 
blood is less than 10 minutes, while binding to IGFBP-3 and the ALS can prolong its 
half life to over 6 hours (McCusker and Clemmons, 1992). The short half life of 
the IGF-I might cause its undetection in the SI, though in the presence of mRNA. 
However, in fusion with LRP, the fusion may have stabilized the IGF-I protein and 
extended its half life. 
Gene silencing, at different levels, might be involved and resulting in failure in 
‘ transgene expression. Transcriptional gene silencing (TGS), as characterized by 
> 
reduced transcription of transgene that shares sequence homology in the promoter 
region in the nucleus and associated with de novo methylation of the promoter region 
of the affected locus (Vaucheret et al” 1998), might have occurred in the IGF-I 
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transformants with 31, PI, and SIA as no IGF-I transcript could be detected. Since 
the IGF-I transgene was inserted into plant genome by random, they might integrate 
into hypermethylated chromosomal regions. This position effect might lead to the 
spreading of the methylation pattern to transgenes which inactivating transgene 
transcription (Prols and Meyer, 1992). 
On the other hand, transgene transcription might have occurred but the 
transcripts were degraded and could not be accumulated to a detectable level. In 
this case, post-transcriptional gene silencing (PTGS), which reduced stable transcript 
accumulation in the cytoplasm after transcription of the transgene via 
sequence-specific RNA degradation and associated with coding sequence 
methylation (Vaucheret et al., 1998), might occur. 
Since the IGF-I and IGFBP-3 genes could be transcribed in the transformants 
PB, IGFu, BGFu and SI despite the presence of steady-state mRNA, position effect, 
TGS or PTGS might not be applicable. Gene silencing might occur at the 
translation and/or post-translation levels in these four transformant lines. 
‘Translation of these transcripts might not be efficient or the resulting proteins were 
unstable and degraded after translation. 
Silencing of the transgene is quite frequently observed in plants. Gene 
silencing occurs when multiple copies of transgene integration exist at one or more 
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sites. It has been suggested by Assaad et al. (1993) that plants possess a 
homology-detection mechanism that induces the hypermethylation of multiple 
homologous sequences. 
There are certain ways to prevent the occurrence of inactivation such as 
selection for plants with single copy rDNA; developing methods for single-copy 
integration; avoiding repetitive homologous sequences; flanking rDNA with scaffold 
attachment regions; selection for stable rDNA expression and developing 
site-specific recombination systems (Kusnadi et al., 1997). Furthermore, different 
base-composition between rDNA and the integration site, detrimental effects of 
sequences adjacent to the rDNA integration site or over-expression effects have been 
shown to reduce gene silencing as well (Kusnadi et al.’ 1997). 
I 
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5.7 Future perspectives 
In this study, recombinant IGF-I and IGFBP-3 proteins have been produced in 
transgenic tobacco. It is important to determine whether these proteins possess 
biological activities in mammalian cells. The further analysis of the recombinant 
proteins should include in depth assessment of their biological activities, which may 
have important therapeutic benefit in the management of insulin resistance and 
diabetes mellitus. 
Second and third generations of plant have been germinated to obtain 
homozygous transgenic plants for further protein production and to maintain the 
transgenic lines for storage and use. Recombinant proteins from homozygous lines 
of transformants IFu and BFu will be separated from seed total protein extract by the 
affinity chromatography method. By attaching specific antibodies to IGF-I and 
IGFBP-3 to the column matrix, the target proteins will be retained. After washing 
out the impurities, the target proteins will be eluted by either high or low pH, or high 
salt solutions (Reifsnyder et al.’ 1996). The purified protein will be subjected to EK 
digestion. EK will be used to cleave the recombinant protein from the LRP 
backbone. In vitro binding assay will be performed to determine the binding 
capacity of rhIGFBP-3 to rhIGF-I (Bayne et al.’ 1988). 
The biological activity of the purified rhlGF-I will be tested on rat skeletal 
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muscle cell line (L6) and compare with that of the native IGF-I. Similar to insulin, 
IGF-I has been shown to cause membrane ruffle and glucose uptake in the muscle 
cells (Khayat et al.，2000; Patiag et al., 2000). rhIGF-I will be tested in parallel 
with insulin to compare their biological activities. After stimulation with insulin or 
rhIGF-I, the effect on remodeling of the cytoskeleton will be investigated by 
immunofluorescence (Tong et a!.’ 2001). Insulin-mediated glucose uptake will be 
measured by radioisotope labeled 2-deoxy-glucose assay (Tong et al” 2001). 
IGFBP-3 has been shown to mediate many growth-inhibitory effects in breast 
cancer cells and even to interact directly with some of the receptors for cell growth 
inhibition or apoptosis induction (Schedlich and Graham, 2002). In our pilot 
experiment with the rhIGFBP-3, the crude seed protein extracted from transgenic 
tobacco plants was subjected to biological activity test using human breast cancer 
cell line (MCF-7) by MMT assay. Preliminary results showed that the cell growth 
was inhibited by the addition of total seed protein extract containing the equivalence 
of 100-300ng/ml rhIGFBP-3 protein. If the recombinant proteins have similar 
. funct ional activity and structure to the human protein counterparts, they can be tested 
in animal models for therapeutic purpose. 
In this study, we demonstrated that IGF-I and IGFBP-3 can be synthesized in 
transgenic tobacco plants. Proteins can be accumulated in high content in seeds and 
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stable proteins can be stored (Daniell et al., 2001). It is therefore plausible that 
other transgenic plants can be modulated to produce large quantity of recombinant 
IGF-I and IGFBP-3 proteins. Cereal crops, like rice, are recognized as model 
bioreactors to produce pharmaceutically and commercially important proteins and 
vaccines (Fischer and Emans, 2000). The recombinant protein can be transported 
and accumulated in the protein bodies of the endosperm to increase the yield and 
could account up to 30% of the total protein in the grain or 2.7% of the net dry 
weight of the grain (Liu, 2002). Rice, consumed daily by over 40% of world's 
population (Huang et al” 2001)，and is well-established in agricultural practices 
worldwide. Further studies will be performed to introduce IGF-I and IGFBP-3 




Chapter 6 Conclusion 
Westernization, sedentary life style and ageing contribute to the rapid increase 
in the prevalence of diabetes in Hong Kong Chinese. Compared to the Caucasians, 
a higher proportion of Chinese diabetic patients have pancreatic P-cell failure. The 
combination of age-related decline in IGF-I and insulin deficiency leads to 
derangement of the GH/IGF-I axis. It is plausible that adjunct therapy with rhIGF-I 
and rhIFGBP-3 will alleviate insulin resistance and improve glycaemic control in 
patients with diabetes. 
In this study, various IGF-I and IGFBP-3 constructs with different spatial 
expression patterns were designed and introduced into the tobacco plants by 
Agrobacterium-mQdidXQ^ transformation. Successful integration of transgene into 
tobacco genome was confirmed by genomic PCR and Southern blot analysis. The 
IGF-I and IGFBP-3 transcripts were also detected by northern blot analysis. From 
the results of western blot analysis, we demonstrated that human IGF-I and IGFBP-3 
‘ c o u l d be produced by transgenic plants of the LRP fusion or phaseolin targeting 
I 
construct (IFu, BFu, SB and SBA), amounting to 0.4% of the total seed protein. 
This study advances our understanding on the use of plant as a bioreactor. The 
availability of functional rhIGF-I and rhIGFBP-3 at low cost and sufficient quantity 
131 
will encourage more research on the therapeutic use of these proteins in different 
• .、-
disease states. 
, • •,、： 
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